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Choline, an essential nutrient, is critical in maintaining biomembrane integrity (via 
phosphatidylcholine) and supplying methyl groups for one-carbon metabolism (via betaine). 
Choline adequate intakes were established for the first time in 1998. However, little is known 
about the impact of pregnancy and genetic variation on choline metabolism and requirements. 
The overall goal of my research was to quantify the effects of pregnancy, genetic variation, and 
choline intake on biomarkers of choline metabolism.  
To achieve this goal, two separate feeding studies that employed stable isotope 
methodology were conducted. Study 1 examined the effect of the methylenetetrahydrofolate 
reductase (MTHFR) 677C→T genetic variant, and choline intake, on biomarkers of choline 
metabolism. Study 2 investigated the effect of pregnancy, and choline intake, on biomarkers of 
choline metabolism. Deuterium labeled methyl-d9-choline was administered in both studies as 
the tracer.   
Study 1 demonstrated that the MTHFR 677TT (versus the 677CC) genotype favors the 
use of choline as a methyl donor. MTHFR 677TT genotype enhanced the conversion of choline 
to betaine. In addition, when a higher choline intake was consumed, more of the choline was 
converted to betaine as opposed to entering the CDP-choline pathway for phosphatidylcholine 
synthesis among men with MTHFR 677TT (versus 677CC) genotype.  
Study 2 demonstrated that pregnancy alters choline metabolism with 10-60% lower 
circulating concentrations of choline derived methyl donors among pregnant versus nonpregnant 
women. Stable isotope data suggested that pregnancy increased choline partitioning to the CDP-
choline pathway at the expense of betaine synthesis, and also increased the use of choline-
derived methyl groups for methionine synthesis and phosphatidylcholine synthesis through the 
phosphatidylethanolamine N-methyltransferase (PEMT) pathway. Despite the upregulation of 
both pathways for phosphatidylcholine synthesis, PEMT-phosphatidylcholine was selectively 
transferred to the fetus. Consumption of 930 (versus 480) mg choline/d increased circulating 
concentrations of choline derived methyl donors, restored the partitioning of choline between the 
CDP-choline and choline oxidative pathways to the nonpregnant state, and enhanced the use of 
choline as a methyl donor in both maternal and fetal compartments.  
In conclusion, choline requirements are elevated in those with the MTHFR 677TT 
genotype and among third trimester pregnant women, and current recommendations may be 
suboptimal for these population sub-groups. 
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PREFACE 
SPECIFIC AIMS 
The overarching goal of my dissertation research was to quantify the effects of pregnancy, 
genetic variation, and choline intake on biomarkers of choline metabolism. In order to achieve 
this goal, two separate 12 wk feeding studies that employed stable isotope methodology were 
conducted. 
Aim 1: To test the hypothesis that MTHFR C677T genotype and choline intake alter the 
metabolic use of orally consumed choline. This hypothesis was tested by evaluation of 
enrichments and enrichment ratios of choline derivatives in men with the MTHFR 677CC or 
677TT genotype consuming ~ 15% of controlled choline intakes (550 or 1100 mg choline/d) as 
deuterium labeled methyl-d9-choline for the last 3-wk of a 12 wk controlled feeding study. 
Results are presented in chapter 1.  
Aim 2: To test the hypothesis that pregnancy and choline intake alter markers of choline 
metabolism. This hypothesis was tested by evaluation of the blood and urinary concentrations of 
choline derivatives in nonpregnant and third trimester pregnant women consuming controlled 
choline intakes of either 480 (~ choline AI for pregnant women) or 930 mg choline/d for 12 wk. 
Results are presented in chapter 2. 
Aim 3: To test the hypothesis that pregnancy and choline intake alter the metabolic use of 
orally consumed choline. This hypothesis was tested by evaluation of enrichments and 
enrichment ratios of choline derivatives in pregnant and nonpregnant women consuming ~ 22% 
of controlled choline intakes (480 or 930 mg choline/d) as deuterium labeled methyl-d9-choline 
during the last 6-wk of a 12 wk controlled feeding study. Results are presented in chapter 3.  
 
 x 
This dissertation research yielded two published peer-reviewed articles (Chapters 1 & 2) 
and one original research manuscript, which will be submitted for publication within the next 
few months (Chapter 3).  
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BACKGROUND 
Choline metabolism 
Choline (2-hydroxyethyl-trimethyl-ammonium), a quaternary saturated amine, is an 
essential nutrient. Through its derivatives (Figure 1), choline plays indispensible roles in 
supplying methyl groups for one-carbon metabolism (via betaine) and maintaining biomembrane 
integrity (via phosphatidylcholine) [1].  
 
Figure 1 legend  
Simplified diagram of choline related one-carbon metabolic pathways.  
White circles indicate labile methyl groups associated with choline 
Abbreviations: CDP-choline, cytidine diphosphate-choline; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, 
tetrahydrofolate; 5-CH3-THF, 5-methyl-tetrahydrofolate; 5,10-CH2-THF, 5,10-methylene-
tetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase; PEMT, 
phosphatidylethanolamine N-methyltransferase 
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Choline is a source of methyl groups for one-carbon metabolism 
  Choline can be oxidized to betaine, which donates a methyl group to homocysteine, 
producing methionine. The oxidation of choline also generates dimethylglycine (DMG) and 
methylglycine (sarcosine) in a sequential demethylation manner: choline → betaine → DMG → 
sarcosine. The methyl groups associated with these choline-derived methyl donors (i.e., DMG 
and sarcosine) can be used in folate mediated one-carbon (1-C) metabolism for the biosynthesis 
of nucleotides and methionine. Methionine serves as a precursor to S-adenosylmethionine (SAM), 
which is the major biological methyl donor for more than 60 methylation reactions, including 
DNA and histone methylation. Therefore, choline availability through influencing DNA/histone 
methylation has a downstream effect on genome stability and gene expression [1, 2].  
There is an alternative homocysteine methylation step that does not utilize betaine.  This 
pathway is dependent on the folate metabolite, 5-methyl-tetrahydrofolate (5-methylTHF). Thus, 
the metabolism of choline and the metabolism of folate intersect at the step of homocysteine 
methylation. The 5-methylTHF is produced from 5, 10-methyleneTHF by the enzyme 5, 10-
methyleneTHF reductase (MTHFR). If the activity of MTHFR is modified, this may affect the 
availability of 5-methylTHF for methyl donation. Changes in folate derived methyl donor 
availability may subsequently affect the demand for betaine as  a source of methyl groups for 
homocysteine remethylation [3]. 
A single nucleotide polymorphism (SNP) has been identified in the MTHFR gene 
(677C→T) [4].  Homozygotes for this SNP (MTHFR 677TT) have diminished enzyme activity 
versus MTHFR 677CC [4]. In the United States, the prevalence of the MTHFR 677TT genotype 
varies among different ethnic groups with an average of 10%. However the prevalence is 20% in 
people of Mexican descent [5]. MTHFR 677TT homozygosity is associated with an elevated 
 xiii 
homocysteine level especially under conditions of folate insufficiency [6] and thus may increase 
the demand for choline derived methyl groups for homocysteine remethylation.  
 
Choline and phosphatidylcholine inter-conversion 
  The choline derivative phosphatidylcholine may be produced via two pathways. The 
cytidine diphosphate-choline (CDP-choline) pathway utilizes the intact choline moiety to 
produce phosphatidylcholine. The CDP-choline pathway accounts for ~70% of total 
phosphatidylcholine production [7, 8]. Alternatively, phosphatidylcholine may be produced by 
three sequential methylations of phosphatidylethanolamine. This reaction is catalyzed by 
phosphatidylethanolamine N-methyltransferase (PEMT) with three SAM molecules as the 
methyl donors. The PEMT enzyme is mainly expressed in the liver, and PEMT mediated 
phosphatidylcholine production accounts for ~30% of total phosphatidylcholine production [9].  
Phosphatidylcholine is subject to hydrolysis by several phospholipases, which ultimately 
can convert phosphatidylcholine to free choline [10]. Hydrolysis of phosphatidylcholine from the 
CDP-choline pathway back to free choline provides no net gain of choline. However, hydrolysis 
of the PEMT derived phosphatidylcholine (which was initially produced from 
phosphatidylethanolamine that does not contain choline moiety) provides a net gain in free 
choline. Thus, PEMT mediated phosphatidylcholine synthesis is considered to be the denovo 
choline synthesis pathway and can supply in part the demand for choline.  
 Phosphatidylcholine is a major constituent of biomembranes. Choline requirements are 
thus high when a large quantify of phosphatidylcholine is needed to support rapid cell division 
and growth (e.g., during pregnancy) [11]. Phosphatidylcholine is also a major constituent of 
very-low-density lipoproteins (VLDL), which export lipids out of the liver [12]. Thus the most 
 xiv 
obvious clinical symptom of choline deficiency is fatty liver, due to the lack of 
phosphatidylcholine for the synthesis and secretion of VLDL.  
 
Choline adequate intakes (AI) 
Despite the ability to endogenously produce choline via the PEMT pathway, studies have 
demonstrated that consuming a choline depletion diet resulted in liver dysfunctions [13]. This 
suggests that endogenous synthesis through the PEMT pathway alone is unable to meet choline 
demand. Therefore, the Food and Nutrition Board of the Institute of Medicine established dietary 
recommendations for choline for the first time in 1998 based on the amount needed to prevent 
liver dysfunction [14].  
For adult men: 
The choline AI for men is set at 7 mg/kg/day (~550mg/day) based on a single study 
conducted by Zeisel et al [13] reporting that a choline intake level of 500 mg/d (7 mg/kg/day) 
was adequate to prevent the choline deficiency induced liver malfunction evidenced by elevated 
serum alanine aminotransferase activity.  
For adult women: 
The AI for adult women was extrapolated from the AI for men, giving an AI of 425 mg/d.  
For pregnant women: 
Pregnancy is associated with a higher demand for choline due to accelerated one-carbon 
metabolism and the synthesis of new membranes as cells undergo division. IOM acknowledged 
this enhanced demand and set the AI for pregnant women (450 mg/d) as 25 mg/d higher than that 
of nonpregnant women (425 mg/d). The 25 mg/d incremental amount was the estimated choline 
demand to support fetal and placental growth and was largely based on animal data.  
 xv 
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CHAPTER 1 
MTHFR C677T genotype influences the isotopic enrichment of one-carbon metabolites 
in folate-compromised men consuming d9-choline
*
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
Yan J, Wang W, Gregory JF, Malysheva O, Brenna JT, Stabler SP, Allen RH, Caudill MA. 
MTHFR C677T genotype influences the isotopic enrichment of one-carbon metabolites in 
folate-compromised men consuming d9-choline. Am J Clin Nutr 2011; 93:348-55. 
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ABSTRACT 
Background:  Homozygosity for the variant 677T allele in the methylenetetrahydrofolate 
reductase (MTHFR) gene increases the requirement for folate and may alter the metabolic 
use of choline. The choline adequate intake is 550 mg/d for men although the metabolic 
consequences of consuming extra choline are unclear. 
Objective: Using deuterium labeled choline (d9-choline) as a tracer, the differential effects 
of the MTHFR C677T genotype and varied choline intake on the isotopic enrichment of 
choline derivatives were determined in folate-compromised men.   
Design: Mexican American men with the MTHFR 677CC or 677TT genotype consumed a 
diet providing 300
 
mg choline/d plus supplemental choline chloride for total choline intakes 
of 550 (n=11; 4 677CC, 7 677TT) or 1100 mg/d (n=12; 4 677CC, 8 677TT) for 12-wk. 
During the last 3-wk, 15% of the total choline intake was provided as d9-choline.  
Results: Low but measurable enrichments of the choline metabolites were achieved 
including d3-phosphatidylcholine (PtdCho), a metabolite produced in the endogenous 
pathway using choline derived methyl groups.  Men with the MTHFR 677TT genotype had a 
higher urinary enrichment ratio of betaine to choline (P=0.041), a higher urinary enrichment 
of sarcosine (P=0.041), and on the 1100 mg/d choline intake level, a greater plasma 
enrichment ratio of d9-betaine to d9-PtdCho (P=0.033).  
Conclusions: These data show for the first time in humans that choline itself is a source of 
methyl groups for denovo PtdCho biosynthesis and demonstrate that the MTHFR 677TT 
genotype favors the use of choline as a methyl donor.
 3 
INTRODUCTION 
Choline is an essential micronutrient that serves as the precursor molecule for several 
important compounds including the phospholipids phosphatidylcholine (PtdCho) and 
sphingomyelin, the neurotransmitter acetylcholine, and the methyl donor betaine (1) (Figure 
1). PtdCho and sphingomyelin are abundant in cellular membranes and have structural and 
signaling functions; PtdCho is also the major phospholipid in lipoproteins with influences on 
lipid metabolism and transport (2).  Most PtdCho (~ 70%) is synthesized by the cytidine 
diphosphate (CDP)-choline pathway in which choline itself serves as the substrate; the 
remainder is synthesized de novo via phosphatidylethanolamine N-methyltransferase 
(PEMT), a S-adenosylmethionine (SAM)-dependent enzyme that sequentially methylates 
phosphatidylethanolamine to PtdCho (3). The methyl groups associated with SAM are 
originally derived from folate, choline (betaine) and/or methionine (4). In addition to PtdCho 
biosynthesis, these one-carbon units may be used for the biosynthesis of several metabolites, 
hormones, and neurotransmitters, and for the methylation of DNA with subsequent effects on 
gene expression and genome stability (5). Severe choline deficiency can cause metabolic 
disturbances such as fatty liver (6, 7), muscle damage (8), and aberrant gene expression as a 
result of alterations in DNA methylation patterns (9, 10).  Associations between low dietary 
choline intake and increased risk for inflammation (11); birth defects (12); and breast cancer 
(13) also have been reported.   
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Figure 1 legend  
The metabolic fate of the orally consumed deuterium labeled choline.  The d9-choline tracer 
contained deuterium-labeled methyl groups facilitating the examination of the metabolic fate 
of choline-derived methyl groups in addition to the intact molecule. Abbreviations used: 
THF: tetrahydrofolate; MTHFR: 5,10-methylenetetrahydrofolate reductase; PEMT: 
phosphatidylethanolamine N-methyltransferase; GNMT: glycine N-methyltransferase; CK: 
choline kinase; CHDH: choline dehydrogenase 
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Based primarily on the amount of choline needed to prevent liver dysfunction, choline 
adequate intake (AI) levels of 425 and 550 mg/d for women and men respectively were 
established in 1998 (14). The metabolic requirement for choline is likely higher in individuals 
with compromised folate status because betaine (oxidized from choline) shares the 
homocysteine remethylation step in one carbon metabolism with 5-methyl-tetrahydrofolate 
(THF) (14).   5-methylTHF is derived from 5,10-methyleneTHF in a reaction catalyzed by 
5,10-methyleneTHF reductase (MTHFR). The availability of 5-methylTHF, the main folate 
coenzyme in circulation, is modified by a common single nucleotide polymorphism, 
677C→T, in the MTHFR gene (15).    
 We previously reported diminished serum folate and elevated plasma homocysteine 
concentrations in men with the MTHFR 677TT genotype, relative to those with the 677CC 
genotype, after 12 weeks of consuming the folate RDA (16).  The diminished 5-methylTHF 
in men with MTHFR 677TT genotype may result in a higher reliance on betaine as the 
methyl group donor for one carbon metabolism and therefore alter choline 
partitioning/metabolism.   Our finding of lower plasma phosphatidylcholine concentrations in 
this group of men with the MTHFR 677TT genotype (17) is consistent with this working 
hypothesis.    
The objective of this study was to determine the effects of the MTHFR C677T 
genotype and/or varied choline intake on the metabolic use of orally consumed choline.  To 
accomplish this aim, deuterium labeled choline (d9-choline) was consumed orally by men 
with the MTHFR 677CC or TT genotype during the last three weeks of a 12 week controlled 
feeding study. Isotopic enrichment and enrichment ratios (i.e., the proportion of the precursor 
molecule converted to the product molecule) of one carbon metabolites derived from the 
orally consumed labeled choline were evaluated.  
 6 
SUBJECTS AND METHODS  
Subjects and study design 
The men in this study (n=23; 18 to 42y) represent a sub-sample of healthy Mexican 
American men (n=60; aged 18-55 years) pre-selected for the MTHFR 677CC or TT genotype 
and were recruited between June 2005 and September 2006. Additional inclusion criteria 
have been described elsewhere (16). The study was approved by the Institutional Review 
Board for Human Study Participants at Cal Poly Pomona University and written informed 
consent was given by each participant.  Approval to use de-identified samples for the 
measurements made in this study was granted by the Cornell Institutional Review Board for 
Human Subjects. 
 This was a 12-week choline intervention study in which study participants (n=60) 
with the MTHFR 677CC (n=31) or 677TT (n=29) genotype were randomized at baseline to 
300, 550, 1100 or 2200 mg/d choline.  The diet, consumed by all study participants 
throughout the study, provided 300 mg/d total choline, 173 mg/d betaine  as well as 319 μg/d 
natural food folate (16, 17).  The study participants also consumed 70 μg supplemental folic 
acid / d for total folate intakes of 438 μg dietary folate equivalents / d (16).  To achieve the 
target choline intakes of 550, 1100 or 2200 mg/d, unlabeled commercially available choline 
chloride (BCP Ingredients Inc, Verona, MO) was administered for the first 9 weeks as 
previously detailed (16).  During the last three weeks of the study (wk 10-12), a sub-sample 
of the men in the 550 mg/d (n=11; 4 677CC, 7 677TT) and 1100 mg/d (n=12; 4 677CC, 8 
677TT) choline intake groups received 15% of the target dose as d9-choline prepared from 
commercially available [trimethyl-d9]choline chloride (Cambridge Isotope Laboratories Inc, 
Andover, MA; Figure 2).  In the 550 mg/d choline intake group, choline was derived from 
the diet (300 mg/d), unlabeled supplemental choline chloride (167.5 mg/d) and d9-labeled 
supplemental choline chloride (82.5 mg/d).  The supplemental choline chloride (d0+d9) was 
 7 
consumed daily at the breakfast meal.  In the 1100 mg/d choline intake group, choline was 
derived from the diet (300 mg/d), unlabeled supplemental choline chloride (635 mg/d) and 
d9-labeled supplemental choline chloride (165 mg/d).  The supplemental choline chloride 
(d0+d9) was divided into two equal portions (317.5 mg d0-choline plus 82.5 mg d9-choline) 
and consumed at breakfast and dinner.  
 The isotopic enrichment of choline and its metabolites was assessed at the end of the 
study (wk 12) in plasma and urine. Adherence to the study protocol was previously 
established by measurements of serum folate (a sensitive marker of dietary intake) and 
plasma free choline (16, 17).  
 
 
 
 
 
 
 
Figure 2 legend 
Mean intake of dietary total choline and choline chloride either as unlabeled (d0) or labeled 
(d9) choline.   
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Sample collection and MTHFR C677T genotyping 
Baseline and weekly fasting (10h) venous blood samples were collected into serum 
separator gel and clot activated tubes (Vacutainer; Becton Dickinson, Rutherford, NJ) and 
EDTA-coated tubes (Vacutainer), processed, and stored at -80
o
C as previously described 
(18). Twenty-four hour urine collections were obtained at wk 0, 6, and 12, processed and 
stored at -20
o
C as described previously (18). Determination of the MTHFR C677T involved 
polymerase chain reaction, digestion with Hinf1 and electrophoretic separation on an agarose 
gel (19). 
Measurements of plasma and urinary choline metabolites 
Plasma and urinary concentrations of free choline [unlabeled (d0) and d9]; betaine (d0 
and d9); dimethylglycine (d0and d6); and sarcosine (d0 and d3) were determined by liquid 
chromatography tandem mass spectrometry (LC/MS/MS) according to the method of Holm 
et al (20). The system included an LCQ Advantage Mass Spectrometery system (Thermo 
Finnigan) with an electrospray ionization source operated in positive ion mode, a Surveyor 
HPLC system (Thermo Finnigan) and a refrigerated Surveyor autosampler (Thermo 
Finnigan). Urine or plasma (50 μL) was transferred to a 1.5 mL Eppendorf tube, and 100 μL 
of acetonitrile containing 0.1% (v:v) formic acid was added to precipitate proteins.  d13-
choline, d3-betaine, and d3-dimethylglycine (0.2 nmol/L of each) were used as internal 
standards. The mixture was vortexed and centrifuged at 4 ºC. An aliquot of supernatant (120 
μL) was transferred to vials containing 120 μL 0.1% (v:v) formic acid in acetonitrile. The 
separation of choline, betaine and dimethylglycine was achieved using an Alltech® Prevail 
Silica analytical column (2.1×150 mm, 5 μm) and a Alltech® Prevail Silica guard column 
(2.1×7.5 mm, 5 μm) with a mobile phase of 81% filtered acetonitrile and 19% of 0.1% formic 
acid (v:v) in 15mM ammonium formate. The flow rate was 500μL/minute, the injection 
volume was 10 μL and the column temperature was maintained at 25 ºC.The external 
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standard curve for choline (d0 and d9), betaine (d0 and d9), and dimethylglycine (d0and d6) 
was constructed in 25:75 (v:v) 15mM ammonium formate and acetonitrile solution.  
Plasma PtdCho (d0, d3, d6 and d9) was measured by LC/MS as described by Koc et 
al (21) with modifications based on our instrumentation (22) using d4-PtdCho as an internal 
standard. The calculation of enrichment percent (d3-Ptdcho/total Ptdcho; d9-Ptdcho/total 
Ptdcho) was based on the peak area under the curve.  
 Plasma methionine (d0, d3) was measured by gas chromatography-mass spectrometry 
(GC-MS) in negative ion electron capture mode as the n-propyl ester N-heptafluorobutyryl 
derivative using chemical ionization (23) as previously described (24). 
A panel of urinary one-carbon metabolites (i.e., sarcosine, homocysteine, 
cystathionine, cysteine, methionine, aminobutyric acid, glycine and serine) was quantified by 
Gas Chromatography-Mass Spectrometry (GC-MS) following established protocol (25, 26). 
The enrichments of urinary DMG and sarcosine were also determined by GC-MS in a 
separate run in which internal standard was not added. 
Statistical analysis 
To test for differences in the dependent variables of interest (e.g., plasma d9-choline) 
between the MTHFR C677T genotypes and between two different choline intake groups, a 2-
factor ANOVA (choline intake and MTHFR C677T genotype) was performed on each 
dependent variable. Dependent variables whose residuals were not normally distributed were 
log or square root transformed to fit the assumption of the ANOVA model. Effects were 
considered to be significant at P < 0.05 whereas a P < 0.1 was indicative of trends. Data are 
presented as means ± SEM for all dependent variables and were analyzed by SPSS software 
(version 15, SPSS Inc., Chicago, IL). 
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RESULTS  
Characteristics of Study Population 
Table 1 shows indicators of folate and choline status, as well as, concentrations of urinary 
metabolites related to one-carbon metabolism at the end of the 12 week study.  Age and body 
mass index of the study population are also provided. Compared to men with the MTHFR 
677CC genotype, those with the 677TT genotype had lower serum folate (P=0.003) and 
higher plasma homocysteine (P=0.001) concentrations.  The mean age of men with the 
MTHFR 677TT genotype was also lower (P=0.038) relative to those with the 677CC 
genotype.  Compared to men consuming 550 mg/d choline, the 1100 mg/d intake group had 
higher plasma betaine concentrations (P=0.014) and tended to have higher plasma free 
choline concentrations (P=0.052) and greater urinary cystathionine excretion (P=0.086). The 
MTHFR C677T genotype tended to interact with choline intake (P=0.057) to affect urinary 
homocysteine with the highest concentration detected in men with MTHFR 677TT genotype 
in the 1100 mg/d choline intake group. No other differences were detected.
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TABLE 1 
Clinical and biochemical variables at the end of the controlled feeding study (wk 12) in Mexican American men with the MTHFR 677CC or 
677TT genotype consuming choline intakes of 550 or 1100
1
.  
 Choline intake, mg/d  P-values 
Variable 550 1100 All   Genotype Choline Interaction 
Age, y     0.038 0.927 0.604 
677CC 28 (22-42) 26 (19-35) 27 (19-42)*     
677TT 21 (18-27) 22 (20-28) 22 (18-28)     
Total 24 (18-42) 24 (19-35)      
BMI, kg/m
2
     0.652 0.317 0.179 
677CC 24.5 (21-27) 28.8 (20-36) 26.6 (20-36)     
677TT 26.1 (22-30) 25.5 (21-30) 25.8 (21-30)     
Total 25.5 (21-30) 26.6 (20-36)      
Serum folate, nmol/L   0.003 0.676 0.915 
677CC 12.3±1.7 11.6±2.7 11.9±1.5*     
677TT 7.3±0.9 6.9±0.8 7.1±0.6     
Total 9.1±1.1 8.5±1.2      
Plasma tHcy, μmol/L   0.001 0.328 0.336 
677CC 11.7±0.7 11.8±0.7 11.7±0.5*     
677TT 28.5±6.7 40.7±5.7 35±4.5     
Total 22.4±4.9 31.1±5.6      
Plasma choline, μmol/L     0.655 0.052 0.841 
677CC 7.0±0.8 9.4±2.2 8.2±1.2     
677TT 7.4±0.7 10.2±1.1 8.9±0.8     
Total 7.2±0.5 10.0±1.0
#
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Plasma betaine, μmol/L      0.418 0.014 0.755 
677CC 46.0±5.2 66.0±14.0 56±7.9     
677TT 42.6±3.1 58.3±4.7 51±3.5     
Total 43.8±2.6 60.9±5.4
#
      
Plasma total PtdCho (d0+d3+d9), μmol/L   0.498 0.733 0.079 
677CC 1784±166 1532±93 1658±100     
677TT 1492±84 1665±101 1585±68     
Total 1599±88 1621±74      
Urinary choline, μmol/g Cr   0.135 0.085 0.249 
677CC 16.9±6.3 22.7±5.5 19.4±4.1     
677TT 20.3±5.5 48.2±10 35.3±7.1     
Total 19.0±4.0 40.6±8.2      
Urinary betaine, μmol/g Cr  0.29 0.853 0.925 
677CC 80.2±29 67.6±18 74.8±17     
677TT 124.6±55 120.5±31 122.4±29     
Total 106.9±34 104.7±23      
Urinary DMG, μmol/g Cr  0.159 0.957 0.088 
677CC 86.6±23 35.7±2 69.6±18     
677TT 76.7±20 130.8±26 105.8±18     
Total 80.7±10 109.7±9      
Urinary sarcosine, μmol/g Cr  0.909 0.123 0.627 
677CC 12.1±1.2 17.7±5.3 14.5±2.4     
677TT 13.1±2.5 16.1±1.7 14.7±1.5     
Total 12.7±1.6 16.5±1.7      
Urinary tHcy, μmol/g Cr  0.012 0.041 0.057 
677CC 4.5±0.9 5.2±0.4 4.8±0.5     
677TT 7.7±3.4 25.8±9.1 18.9±5.2*     
Total 6.3±2.1 18.9±5.5
#
      
Urinary cystathionine, μmol/g Cr  0.787 0.086 0.859 
677CC 4.9±1.2 7.2±1.2 6.0±0.9     
677TT 5.4±1.0 7.3±1.1 6.4±0.8     
Total 5.2±0.7 7.3±0.8
#
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Urinary cysteine, mmol/g Cr  0.731 0.163 0.833 
677CC 0.2±0.03 0.3±0.02 0.2±0.02     
677TT 0.2±0.02 0.2±0.02 0.2±0.01     
Total 0.2±0.01 0.2±0.01      
Urinary methionine, μmol/g Cr  0.356 0.135 0.673 
677CC 6.3±1.7 8.6±1.9 7.4±1.2     
677TT 7.3±2.3 11.4±1.7 9.5±1.5     
Total 6.9±1.5 10.4±1.3      
Urinary aminobutyric acid, μmol/g Cr  0.944 0.517 0.713 
677CC 5.7±1.1 5.9±1.4 5.8±0.8     
677TT 5.4±0.6 6.4±0.7 5.9±0.5     
Total 5.9±0.5 6.2±0.6      
Urinary glycine, mmol/g Cr  0.417 0.197 0.506 
677CC 0.9±0.2 0.8±0.2 0.8±0.1     
677TT 1.1±0.2 0.8±0.1 0.9±0.1     
Total 1.0±0.1 0.8±0.1      
Urinary serine, mmol/g Cr  0.408 0.543 0.929 
677CC 0.2±0.04 0.2±0.03 0.2±0.02     
677TT 0.3±0.04 0.2±0.04 0.2±0.03     
Total 0.2±0.03 0.2±0.03      
1
Data are mean ± SEM or (range); n = 3-8 per group. BMI, body mass index; Cr, creatinine; DMG, dimethylglycine; PtdCho, 
phosphatidylcholine; tHcy, total homocysteine; 
#
Different from corresponding 550mg/d choline intake group, P < 0.05 (2-way ANOVA) 
*Different from corresponding MTHFR 677CC genotype, P < 0.05 (2-way ANOVA). 
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Effects of choline intake and MTHFR C677T genotype on the isotopic enrichment and 
enrichment ratios of choline metabolites [Enrichment = labeled metabolite / (labeled + 
unlabeled metabolite]; [Enrichment ratio = enrichment of product / enrichment of precursor] 
Label was detected at acceptable signal-to-noise ratios in most choline metabolites 
(Figure 3).  Greater plasma enrichments of choline (P=0.029), betaine (P = 0.004), d3-
PtdCho (P = 0.005) and d9-PtdCho (P = 0.009; Figure 3A) were observed in the 1100 versus 
the 550 mg/d choline intake group. Enrichments of plasma methionine (P=0.075), urinary 
choline (P=0.077) and urinary betaine (P=0.014) were also greater in the higher choline 
intake group (Figure 3A). However, choline intake did not affect the enrichment ratios of 
product:precursor metabolites (ie, betaine:choline, methionine:betaine, methionine:choline, 
d3-PtdCho:choline, d3-PtdCho:betaine) indicating that the enrichment of precursors and 
products were equivalently affected. 
The MTHFR 677TT genotype yielded a lower enrichment of urinary choline 
(P=0.091) and a greater urinary betaine to choline enrichment ratio (P=0.041) which suggests 
that flux through choline dehydrogenase may be greater in men with the 677TT vs 677CC 
genotype (Figure 3B).  In addition, the MTHFR C677T genotype and choline intake 
interacted to affect the plasma enrichment ratio of betaine to PtdCho derived from the CDP-
choline pathway (Figure 3C).  In men with the MTHFR 677TT genotype, the higher choline 
intake yielded a greater betaine to phosphatidylcholine enrichment ratio which suggests that 
betaine oxidation was favored over the use of choline by the CDP-choline pathway; no effect 
of choline intake on this ratio was observed in the 677CC genotype.  No other significant 
effects of either choline intake, MTHFR C677T genotype or the interaction term were 
detected on the measured variables.  
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Figure 3 legend 
Isotopic enrichment of plasma and urinary choline metabolites [labeled metabolite / (labeled 
+ unlabeled metabolite] grouped by choline intake (Panel A; n=10-12 per choline intake 
group), MTHFR C677T genotype (Panel B; n=7 677CC; n=13 677TT) or both (Panel C; n=4-
8 per group) at week 12 in folate-compromised Mexican-American men consuming 15% of 
total choline intake as d9-choline from week 10-12.  Data are presented as means ± SEM and 
were analyzed by a 2-factor ANOVA; P < 0.05 was considered statistically significant. For 
the enrichment ratio of d9-betaine to d9-PtdCho, an interaction between MTHFR C677T and 
choline intake was detected (P=0.03, Panel C).  Thus the data are presented after stratifying 
by the MTHFR C677T genotype.   
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Effects of choline intake and MTHFR genotype on the proportion of PtdCho enrichment 
derived from the PEMT and CDP-choline pathways 
Under the conditions of this study, only d3-PtdCho and d9-PtdCho (but not d6-
PtdCho) were detected at quantifiable levels; therefore, it can be assumed that all of the d9-
PtdCho was derived from the CPD-choline pathway. Notably, neither choline intake nor 
MTHFR C677T genotype affected the plasma enrichment ratio of d3-PtdCho to d9-PtdCho 
(data not shown).  This observation suggests that the proportion of PtdCho derived from each 
of these pathways was unaffected by these variables.  
Effects of choline intake and MTHFR genotype on urinary sarcosine enrichment 
Urinary sarcosine enrichment was higher (P=0.049) in men with the MTHFR 677TT 
vs. 677CC genotype (Figure 4). Choline intake did not affect urinary sarcosine enrichment 
and the interaction term for MTHFR C677T genotype and choline intake was not significant.  
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Figure 4 legend 
Urinary sarcosine enrichment at week 12 according to MTHFR C677T genotype (n=7 
677CC; n=13 677TT) in folate-compromised Mexican-American men consuming 15% of 
total choline intake (550 or 1100 mg/d) as d9-choline from week 10-12. Data are mean ± 
SEM and were analyzed by a 2-factor ANOVA; P < 0.05 was considered statistically 
significant.  Choline intake did not affect urinary sarcosine enrichment and the interaction 
term for the MTHFR C677T genotype and choline intake was not significant 
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DISCUSSION 
 To the best of our knowledge, this is the first human study to employ stable isotope 
methodology to investigate the effects of choline intake and the MTHFR C677T genotype 
(677CC or 677TT) on the metabolic use of exogenous choline.  The d9-choline tracer 
contained deuterium-labeled methyl groups and facilitated our examination of the metabolic 
fate of choline-derived methyl groups in addition to the intact molecule.  In turn, distinctions 
could be made between PtdCho derived from the sequential methylation of 
phosphatidylethanolamine via PEMT which produces d3-PtdCho, d6-PtdCho and less likely 
d9-PtdCho versus PtdCho derived from intact choline by the CDP-pathway which yields only 
d9-PtdCho (Figure 1). Because d6-PtdCho was below the detection limits in the present 
study, it was assumed that all of the d9-PtdCho was derived from the CPD-choline pathway. 
The d3 labeling of PtdCho demonstrates for the first time in humans that choline itself 
is a source of methyl groups for the denovo biosynthesis of the choline moiety through the 
PEMT pathway, a finding consistent with a cell culture model using rat primary hepatocytes 
(27). The observed d3 labeling of plasma methionine suggests that cellular pools of S-
adenosylmethionine (SAM) were similarly labeled and, thus, served as methyl donors in d3-
PtdCho synthesis by PEMT. Although the PEMT pathway is traditionally considered to be 
most important when dietary choline intake is low (28), d3 labeling of the PtdCho pool 
occurred under conditions of high choline intake (i.e., 1100 mg/d or two times the AI). 
Notably, the PtdCho molecules derived from the PEMT and CDP-choline pathways are 
molecularly distinct (29) with PEMT-derived PtdCho containing more polyunsaturated fatty 
acids including docosahexaenoic acid (DHA). Hence a possible caveat of increasing dietary 
intake of choline may be reducing the activity of the PEMT pathway which, in mice, results 
in decreased concentrations of circulating DHA (30).  However, based on the enrichment 
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ratio of d3-PtdCho to d9-PtdCho, the relative proportions of PtdCho derived from each 
pathway were not altered by the choline intakes used in this study.  
In the present study, we hypothesized that varied choline intake would affect the 
partitioning of choline such that a higher intake would favor its oxidation.  However, the 
enrichment of products and precursors (i.e., d9-PtdCho/betaine; betaine/choline; 
DMG/choline) were affected to a similar extent suggesting that a doubling of choline intake 
did not alter the metabolic use of orally consumed choline (i.e., proportion of choline 
entering the oxidative pathway or the extent of its catabolism).    
Simple one pool constant infusion kinetics requires that enrichments decrease as label 
moves from pool to pool. Our observed increase in isotope enrichment from precursor d9-
choline to several products in blood and urine indicates that pools are in flux and that more 
than one precursor pool exists for derivation of subsequent products. For instance, we can 
speculate that the high enrichment of betaine, compared to choline, is due to: (i) a rise and 
fall of newly absorbed dietary choline as it is rapidly transported across the gut to the blood 
stream; and/or (ii) an increased release of more enriched products as a result of gut-level 
oxidation of choline to methylamines.  
The observed greater enrichment of urinary metabolites than its plasma counterpart is 
likely due to the timing differences between the urine and blood collections. Similar to the 
kinetic curve in plasma, urinary metabolite enrichment is probably highest within several 
hours after dosing and declines thereafter reaching its lowest value the next day before 
dosing. Therefore the 24-h urine and fasting blood collections probably captured different 
phases of the kinetic curves with plasma enrichment reflecting the lowest point but urinary 
enrichment reflecting an average status.  
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 MTHFR produces 5-methylTHF which, like betaine, can be used to remethylate 
homocysteine to methionine.  The MTHFR 677TT genotype tends to yield diminished tissue 
concentrations of 5-methylTHF, particularly under conditions of folate inadequacy. Notably, 
in the present study, men with the MTHFR 677TT genotype had markedly diminished 
concentrations of serum folate (consisting mostly of 5-methylTHF; Table 1) such that 47% (7 
of 15 participants) had serum folate concentrations in the deficient range (ie, < 6.8 nmol/L; 
data not shown). Although, serum folate was also diminished in men with the MTHFR 
677CC genotype (Table 1) only one participant had serum folate in the deficient range. As a 
result, the demand for betaine as a source of labile methyl groups for homocysteine 
remethylation may be higher in persons with the MTHFR 677TT genotype. The higher 
urinary enrichment ratio of betaine to choline in men with the 677TT genotype is consistent 
with this working hypothesis as it implies enhanced flux through choline dehydrogenase, the 
enzyme responsible for oxidizing choline to betaine. The higher plasma enrichment ratio of 
betaine to CDP-choline derived PtdCho in men with the MTHFR 677TT (relative to the 
677CC genotype) on the higher choline intake is also consistent with an increased demand 
for betaine among MTHFR 677TT individuals as it suggests that more of the free choline 
was converted to betaine as opposed to entering the CDP-choline pathway.  Increased 
demand for betaine in MTHFR deficiency has been reported in rodent studies as evidenced 
by diminished concentrations of hepatic phosphocholine and betaine concentrations in 
MTHFR +/- mice relative to +/+ mice (31). 
The higher urinary enrichment of d3-sarcosine in men with the 677TT genotype is 
likely due to the faster oxidation of exogenous choline (choline → betaine → 
dimethylglycine → sarcosine) in these men and is consistent with their increased reliance on 
choline as a source of methyl groups.  Sarcosine is also produced from glycine in a cytosolic 
reaction catalyzed by glycine N-methyltransferase (GNMT), an enzyme subject to reciprocal 
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regulation by SAM (positive cooperativity) and 5-methyltetrahydrofolate (allosteric 
inhibition) (32, 33). Given the lower serum folate in this group of men (Table 1), it is 
possible that a less inhibited GNMT led to greater production of sarcosine (and 
homocysteine) in those with the 677TT genotype.  
Finally, these data show that daily oral administration of a choline tracer over a three 
week period leads to measurable enrichments in choline and its derivatives in humans. As 
such, these data can provide guidance for future studies designed to quantitatively assess the 
impact of varied choline intake or genetic variation on choline metabolism. The multiple 
methyl labeling strategy that we employed also suggests that inputs from SAM for PEMT-
derived PtdCho can be estimated by conventional mass isotopomer distribution analysis (34), 
although somewhat higher labeling would be required to enable measurements of the d6 
isotopomer which was below the detection limit in the present study. In principle, the mass 
spectra yield relative abundances of d0, d3, d6, and d9 choline isotopomers. The d3 and d6 
concentrations represent the minimum of two isotopomers required to calculate enrichment 
of the precursor methyl pool. Analysis of that labeling would enable an estimate of the 
dilution and net flux of dietary choline-derived methyl groups as they pass through the PEMT 
pathway
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CHAPTER 2 
Maternal choline intake modulates maternal and fetal biomarkers of choline 
metabolism in humans
*
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ABSTRACT   
Background:  In 1998, choline adequate intake (AI) levels of 425 and 450 mg/d were 
established for nonpregnant and pregnant women, respectively. However, no dose response 
studies have been conducted to evaluate the effects of pregnancy or maternal choline intake 
on biomarkers of choline metabolism. 
Objective: We sought to quantify the effects of pregnancy and maternal choline intake on 
maternal and fetal indicators of choline metabolism.   
Design: Healthy pregnant (n = 26, wk 27 gestation) and nonpregnant (n = 21) women were 
randomized to 480 or 930 mg choline/d for 12-wk. Fasting blood samples, placental tissue 
and umbilical cord venous blood were collected and analyzed for choline and its metabolites. 
Results:  Regardless of choline intake, pregnant women had higher (P < 0.001) circulating 
concentrations of choline (30%) but lower (13-55%; P < 0.001) concentrations of betaine, 
dimethylglycine, sarcosine and methionine. Obligatory losses of urinary choline and betaine 
were ~ 2-4 times greater (P ≤ 0.02) among pregnant women. A higher choline intake yielded 
higher (12-46%; P ≤ 0.08) concentrations of choline, betaine, dimethylglycine and sarcosine 
in both pregnant and nonpregnant women without affecting urinary choline excretion. The 
higher maternal choline intake also led to a doubling (P = 0.002) of dimethyglycine in cord 
plasma.  
Conclusions: These data suggest that an increment of 25 mg choline/d to meet the demands 
of pregnancy is insufficient, and demonstrate that a higher maternal choline intake increases 
the use of choline as a methyl donor in both maternal and fetal compartments.  
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INTRODUCTION 
 Choline, a micronutrient commonly grouped with the B-vitamins, is required for the 
biosynthesis of phosphatidylcholine, the main component of cell membranes, and for the 
formation of the cholinergic neurotransmitter acetylcholine.  Following its oxidation to 
betaine, choline is also a major dietary source of methyl groups, which can be transferred to 
DNA and histones in a S-adenosylmethionine (SAM) dependent reaction. DNA and histone 
methylation (i.e., epigenetic modifications) can in turn exert lasting effects on gene 
expression [1]. The oxidation of choline also generates dimethylglycine (DMG) and 
methylglycine (sarcosine) in a sequential demethylation manner: choline → betaine → DMG 
→ sarcosine. The methyl groups associated with these choline-derived methyl donors (i.e., 
DMG and sarcosine) can be used in folate mediated one-carbon (1-C) metabolism for the 
biosynthesis of nucleotides and methionine [2]. 
Pregnancy is associated with a higher demand for choline due to accelerated 1-C 
metabolism and the formation of new membranes as cells undergo division [3].  Pregnancy 
causes a pronounced reduction of choline pools in rodents consuming a normal chow diet [4],  
indicating that the need for this nutrient by the mother and the fetus may exceed the amount 
consumed by the mother and the amount produced by the endogenous pathway (i.e., 
phosphatidylethanolamine N-methyltransferase pathway).  Furthermore, supplementing the 
maternal rat diet with additional choline (approximately 4 times the amount in normal chow) 
leads to a significant enhancement of memory function of the adult offspring [5, 6] and 
substantially lessens aging-related memory decline [7, 8].  The long-lasting beneficial effects 
of maternal choline supplementation on cognitive function may arise, at least in part, from 
modifications of DNA methylation secondary to the use of choline as a methyl donor. 
Although few studies have addressed the adequacy of human choline intake during 
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pregnancy, dietary choline intake [9] and mid-gestation maternal serum total choline [10] are 
inversely associated with the risk of having a baby with a neural tube defect. 
  In 1998, dietary choline recommendations in the form of adequate intakes (AIs) were 
established for the first time by the Food and Nutrition Board of the Institute of Medicine 
[11]. The choline AI for pregnant women, 450 mg choline/d, is largely based on the AI for 
nonpregnant women (425 mg choline/d), which was extrapolated from a single study 
conducted in men and designed to prevent liver dysfunction [11].  An increment of 25 mg 
choline/d was added to the AI of nonpregant women to support fetal and placental growth 
and was largely based on animal data.  Thus additional studies examining the effect of 
pregnancy and maternal choline intake on biomarkers of choline metabolism are needed to 
scientifically inform the development of dietary recommendations that optimize maternal 
health and fetal well-being.  
The goals of this study were to quantify the effects of pregnancy on choline-derived 
methyl donors and related 1-C metabolites (e.g., homocysteine) under conditions of 
controlled intake and to determine whether maternal choline intake modulates these 
metabolic parameters in maternal, placental and fetal compartments.
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STUDY PARTICIPANTS AND METHODS 
Study Participants 
 Third trimester pregnant (gestational wk 27) and nonpregnant control women aged 
>21 y were recruited from Ithaca, NY between January 2009 and October 2010 by the use of 
approved flyers posted at local maternal clinics and at Cornell University. During the 
screening phase, all study volunteers completed a health history questionnaire which included 
(if applicable): participant’s date of birth, gestational age at entry into prenatal care, date of 
last menstrual period, self-reported pre-pregnancy weight, gestational age at present, due 
date, health status, medication use, vitamin/mineral use, and drug/alcohol use.  Entry into this 
study was contingent upon good health status as assessed by a blood chemistry profile, 
complete blood count and medical history questionnaire. Additional inclusion criteria 
included: (i) no tobacco or alcohol product use, (ii) no history of chronic disease, (iii) normal 
kidney and liver function, and (iv) willingness to comply with the study protocol (i.e., eating 
one meal per day at the on-site location and not consuming foods and beverages outside those 
provided by the study). Screening participants were excluded if they (i) were carrying more 
than one fetus, (ii) had pregnancy-associated complications (i.e., preeclampsia, gestational 
diabetes, or intrauterine growth restriction), or (iii) were taking prescription medications 
known to affect liver function.  
 Maternal and newborn information were obtained from medical charts. Maternal 
information included: total weight gained during pregnancy, due date, complications during 
pregnancy, and complications during labor. Newborn information included: date of delivery, 
mode of delivery, gestational age, length, weight, head circumference, and Apgar score.  
 The study protocol was reviewed and approved by the Institutional Review Board for 
Human Study Participant Use at Cornell University and at Cayuga Medical Center (the 
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hospital where participants delivered their babies; Ithaca, NY). Informed consent was 
obtained from all participants prior to their entry into the study.   
Study Design, Diet and Supplements 
   This is a 12-wk controlled feeding study in which healthy pregnant women (wk 27 
gestation; n = 26) with singleton pregnancies and nonpregnant control women (n = 21) 
consumed 480 or 930 mg choline/day. The 7-day cyclical menu (Table 1) provided an 
average of 380 mg choline/day with 142 mg from water soluble forms (free choline, 
phosphocholine, and glycerophosphocholine) and 236 mg from lipid soluble forms 
(phosphatidylcholine, sphingomyelin, and lysophosphatidylcholine). Supplemental choline 
chloride (Balchem, New Hampton, NY) was used to achieve the target intake levels and was 
consumed with a meal of the participant’s choosing as a single bolus of 100 or 550 mg 
choline/d. For the period between completion of the 12-wk study and delivery of the baby, 
pregnant women who had not yet delivered (n = 23) continued to consume their assigned 
choline supplement (100 or 550 mg choline/d). Maternal blood (wk-0, 3, 6, 9, 10 and 12) and 
urine (wk-0, 6, 9 and 12) were collected throughout the feeding phase of the study; a 
maternal blood sample, placenta tissue and cord blood were obtained at delivery.   
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TABLE 1 
Seven-day rotational menu consumed by pregnant and nonpregnant women throughout the 12-week study
1
 
 
Day Breakfast Lunch Dinner Choline (mg) 
Monday 2 Eggs  (50g ea), scrambled 
2 WW toast (28g ea) 
1 Peach cup (133g)
  
*
Juice 
Pesto Sandwich: 
2 WW bread slices (28g ea) 
Pesto (15g) 
Swiss cheese (42g) 
Romaine lettuce (20g) 
Celery sticks (30g) 
Carrot sticks (30g) 
Beef & Cheese Tacos: 
3 Corn tortillas (33g ea) 
Ground beef (80% lean; 105g) 
Cheddar cheese (30g) 
Iceberg lettuce (20g) 
Melon (112g) 
Milk (284g) 
Breakfast: 361 
Lunch: 31 
Dinner: 127 
#
Snack: 27 
Total: 546 
Water soluble: 117 
Lipid soluble: 429 
Tuesday Waffle (130g) 
1 Egg (50g), hard-boiled 
*
Juice 
Tuna Sandwich: 
2 WW bread slices (28g ea) 
Tuna, canned (56g) 
Cheddar cheese (30g) 
Iceberg lettuce (30g) 
Mayonnaise (15g) 
Grapes (100g) 
Spaghetti: 
Cooked pasta (220g) 
Tomato sauce (220g) 
Mushrooms (30g) 
Parmesan cheese (10g) 
Mozzarella cheese (25g) 
Milk  (284g) 
Breakfast: 189 
Lunch: 57 
Dinner: 107 
#
Snack: 27 
Total: 380 
Water soluble: 140 
Lipid soluble: 240 
Wednesday Fitness crunch cereal  (80g) 
Milk (284g) 
1 Box of raisins (42g) 
1 Medium banana (118g) 
*
Juice  
Pastrami Sandwich: 
2 WW bread slices (28g ea) 
Pastrami (24g) 
Swiss cheese (23g) 
Romaine lettuce (30g) 
Cucumber (80g) 
Vegetarian Pizza: 
Dough (200g) 
Tomato sauce (112g) 
Red peppers, jarred  (60g) 
Mushrooms (30g) 
Spinach (20g) 
Mozzarella cheese (50g) 
Apple sauce (28g) 
Milk (284g) 
Breakfast: 96 
Lunch: 52 
Dinner: 95 
#
Snack: 27 
Total: 270 
Water soluble: 152 
Lipid soluble: 118 
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Thursday 
2 Pancakes (100g ea) 
Blueberries, frozen (50g) 
*
Juice  
Egg Salad Sandwich: 
2 WW bread slices (28g ea) 
1 Egg (50g), hard-boiled 
Mayonnaise (20g) 
Romaine lettuce (45g) 
Celery sticks (30g) 
Carrot sticks (30g) 
Beef & broccoli stir-fry: 
Beef (160g) 
Broccoli, frozen (110g) 
Rice (200g) 
Onions, frozen (13g) 
Melon (112g) 
Milk (284g) 
Breakfast: 40 
Lunch: 228 
Dinner: 195 
#
Snack: 27 
Total: 490 
Water soluble: 167 
Lipid soluble: 323 
Friday 1 WW bagel (95g) 
1 Orange cup (133g) 
*
Juice  
Bean Burrito: 
Black beans, canned (40g) 
Cheddar cheese (30g) 
Rice (30g) 
1 Large WW tortilla (59g) 
Lasagna: 
2 WW lasagna noodles, dry 
   (23g ea) 
Tomato sauce (150g) 
Ground beef (80% lean; 60g) 
Cottage cheese (40g) 
Mozzarella cheese (10g) 
Parmesan cheese (10g) 
Summer squash  (40g) 
Zucchini (40g) 
Milk  (284g) 
Breakfast: 50 
Lunch: 34 
Dinner: 168 
#
Snack: 27 
Total: 279 
Water soluble: 137 
Lipid soluble: 142 
Saturday 2 Raspberry muffins (60g ea) 
1 Medium banana (118g) 
*
Juice  
Turkey Sandwich: 
2 WW bread slices (28g ea) 
Turkey (25g) 
Provolone cheese (23g) 
Iceberg lettuce (20g) 
Cucumber (80g) 
Chicken Quesadilla: 
Chicken (65g) 
2 Large WW tortillas  
(59g ea) 
Cheddar cheese (150g) 
Corn, frozen  (100g) 
Milk (284g) 
Breakfast: 122 
Lunch: 38 
Dinner: 178 
#
Snack: 27 
Total: 365 
Water soluble: 137 
Lipid soluble: 228 
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Sunday Oat Granola cereal (80g) 
Milk (284g) 
1 Box of raisins (42g) 
1 Peach cup (133g) 
*
Juice 
Vegetable soup, (396 g) 
Corn muffin (60g) 
Grapes (100g) 
 
Goulash: 
Cooked pasta (200g) 
Beef (120g) 
Onion, frozen (30g) 
Red peppers, jarred (30g) 
Tomatoes, canned (50g) 
Tomato puree (100g) 
Potatoes, canned (35g) 
Pineapple, canned (70g) 
Milk  (284g) 
Breakfast: 64 
Lunch: 59 
Dinner: 170 
#
Snack: 27 
Total: 320 
Water soluble: 149 
Lipid soluble: 171 
 
1
Dietary derived choline includes water-soluble forms (free choline, phosphocholine and glycerophosphocholine) and lipid-soluble forms 
(phosphatidylcholine, sphingomyelin and lysophosphatidylcholine) 
*
Juice choices included apple, crangrape or cranberry 
#
Snacks were provided daily and included: 170 g yogurt (vanilla, raspberry or peach flavored) and 156 g V8 juice. 
Abbreviations used: WW, Whole Wheat
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 All meals and snacks were prepared in the Human Metabolic Research Unit at Cornell 
University. Study participants were required to consume at least one meal per day in the 
metabolic unit Monday through Friday; all other meals/snacks and beverages were provided as 
takeaways. The basic menu provided 2100 kcal/d. Energy intake was modified without affecting 
choline consumption by the addition or subtraction of the following food items: unenriched 
white rice, snack foods (i.e., chips, popcorn, rice cakes and apples) and certain beverages (i.e., 
soda, lemonade and apple juice).  Weight was obtained weekly to monitor weight gain in the 
pregnant women and weight maintenance in the nonpregnant women. The investigators had daily 
contact with the participants throughout the study which enhanced their compliance to the 
dietary regimen.  In addition, the participants were required to verify consumption of each food 
item by completing a daily check list provided by the investigators.   
 The choline stock solution was prepared every 3-mo by dissolving choline chloride in 
autoclaved drinking water, filtering the solution through 0.22 μm filters, dispensing it into amber 
glass bottles, and storing it at 4°C. The molarity of the choline stock solution was determined by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The variability between the 
choline stock solutions throughout the feeding trials was < 5%. Periodic testing of the choline 
stock solution during the 3-mo period indicated no degradation. Appropriate volumes of the 
choline stock solution were dispensed into 50-mL conical tubes, mixed with crangrape juice, and 
stored at -20°C. The choline crangrape cocktail was thawed 1–2 d prior to consumption and kept 
at 4°C. During the last 6-wk of the study (wk 6 - 12), 20% of the total choline intake was 
provided as deuterated methyl-d9-labeled choline (d9-choline; Cambridge Isotope Laboratories, 
Andover, MA). The administration of labeled choline will allow for future examinations of the 
activity of the phosphatidylethanolamine N-methyltransferase pathway through isotopomer 
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analysis. The d9-choline stock solution was prepared the same way as the unlabeled choline 
stock solution and stored at 4°C in amber glass bottles. Appropriate volumes of the d9-choline 
were dispensed into 50 mL conical tubes, mixed with crangrape juice, and stored at -20°C until 
used for consumption. 
 A prenatal multivitamin (Pregnancy Plus, Fairhaven Health, LLC, Bellingham, WA) and 
docosahexaenoic acid (200 mg; Neuromins, Nature's Way Products, Springville, Utah) were 
provided daily and a potassium and magnesium supplement (General Nutrition Corp, Pittsburgh, 
PA) was provided three times per week to all study participants. Throughout the week, all 
supplements (including choline) were consumed at the on-site meal of the participant’s choosing 
(i.e., breakfast, lunch or dinner) under the supervision of the investigators. For the weekend, the 
participants were asked to consume the supplements with a meal of their choosing and to return 
all containers/disposables on Monday.  
 Overall, the study protocol was well-tolerated with 92% of the participants completing 
the study regimen (21 of 22 nonpregnant women, 26 of 29 pregnant women). Reasons for 
stopping the study included nausea (n = 1), early delivery (n = 1), personal challenges (n = 1), 
and food dislikes (n = 1).  Additional information regarding the flow of study participants 
through the screening and intervention phases is shown in Figure 1. 
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Figure 1 legend  
Flow of participants throughout the study screening and intervention phases. 
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Sample collection and processing 
Fasting blood samples (10-h) at wk-0, 3, 6, 9, 10 and 12 were collected in one 10 mL 
serum separator gel and clot-activator tube (SST Vacutainer; Becton, Dickinson and Company, 
Franklin Lakes, NJ); three 10 mL EDTA tubes (Becton, Dickinson and Company); and one 5 mL 
EDTA tube (Becton, Dickinson and Company). The three 10 mL tubes containing EDTA blood 
were put on ice immediately following the blood collection and centrifuged within 90-min at 
1055 x g for 15-min at 4°C.  Buffy coat, plasma and whole blood were removed for genotyping 
and metabolite measurements as previously described [12, 13]. The SST-blood was kept at room 
temperature, allowed to clot and centrifuged at 650
 
x g for 15-min at room temperature. All of 
the biological samples were dispensed into 1.8 mL cryostat vials (CryoTube; NUNC, Roskilde, 
Denmark) and stored at -80°C.    
 Maternal blood and cord blood samples were also collected. Maternal blood samples 
were collected into one 10 mL EDTA tube and one 10 mL SST tube at the hospital within 24-h 
prior to delivery. The cord blood samples were collected into one 10 mL EDTA tube at the time 
of delivery. After collection, the maternal and cord blood samples were placed on ice (or 
refrigerated at 4°C) and processed as described previously within 4-h.    
 The placenta was obtained at delivery and processed at the hospital within 90-min of 
delivery. After removal of the amnion, twenty full thickness tissue biopsies (~ 0.5 cm x 0.5 cm x 
0.5 cm) were taken from four separate locations (i.e., the placenta was visually divided into four 
quadrants). Samples were then rinsed with PBS immediately. One sample from each quadrant 
was randomly selected for RNA extraction and RNA stabilization solution (Qiagen, Valencia, 
CA) was added to prevent RNA degradation. The other samples were flash frozen in liquid 
nitrogen, placed in a cryostat tube and stored temporarily in a canister containing liquid nitrogen. 
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In the lab, all samples were stored at -80°C until subsequent analyses. Anthropometric 
measurements of the whole placenta were obtained and included length, width, depth and 
weight; weight and length of the umbilical cord were also recorded.   
 In addition, 24-h urine samples were collected at wk-0, 6, 9 and 12 in amber wide mouth 
polyethylene bottles (1 L, Nalgene, Rochester, NY) containing 5 g of sodium ascorbate.  
Participants were provided with an insulated bag with ice packs and instructions to keep the 
urine cold at all times. For each collection, the urine was pooled, total volume recorded, and 
urine was dispensed into five 125 mL narrow-mouth field sample bottles (ThermoFisher, 
Waltham, MA). Aliquots of 1 mL were placed into cryostat vials. All samples were stored at -
80°C.    
Analytical Measurements 
Choline content of diet  
The choline content of the diet was determined before starting the study and once during 
the study. Each meal (i.e., breakfast, lunch, dinner, or snack), including beverage, was prepared 
as for the participant’s consumption, and blended with 150 mL of cold 0.1 mol potassium 
phosphate buffer/L (pH = 6.3) that contained 57 mmol ascorbic acid/L. This mixture was 
dispensed into 50 mL conical tubes and stored at -80°C. Total choline and betaine contents were 
determined by the method developed by Koc et al. [14] with modifications based on our 
instrumentation consisting of a TSQ Quantum mass spectrometer with electrospray ionization 
source (Thermo, San Jose, CA) equipped with a refrigerated Accela autosampler (Thermo) and 
an Accela pump with degasser (Thermo). Extraction and quantification procedures were detailed 
previously [15]. The average choline and betaine contents of the diet were 380 and 100 mg/d, 
respectively. Lipid-soluble forms of choline (i.e., phosphatidylcholine, lysophosphatidylcholine 
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and sphingomyelin) accounted for ~ 2/3 of dietary choline content and the remaining 1/3 was 
derived from water-soluble forms of choline (i.e., free choline, phosphocholine and 
glycerophosphocholine) (Table 1).   
Plasma, Serum, Urine and Tissue Measurements  
LC-MS/MS was used to measure plasma, urinary, and placental concentrations of free 
choline, betaine, DMG and/or acetylcholine [16, 17] with modifications based on our 
instrumentation [18]. Serum and urinary homocysteine, sarcosine and methionine were 
quantified by GC-MS using established protocols [19, 20] .  
As recent findings indicate that the gut microbiome influences choline metabolism and, 
in turn, the risk of cardiovascular disease [21], blood and urinary trimethylamine N-oxide 
(TMAO), a gut-flora-dependent choline oxidative metabolite, were also measured by the method 
of Wang et al. [21] with modifications based on our LC-MS/MS instrumentation. Briefly, urine 
(5 μL) or plasma (50 μL) were spiked with 13C3-TMAO as an internal standard and mixed with 
acetonitrile containing 0.1% formic acid to precipitate protein. After vortexing, the samples were 
centrifuged (10,600 x g for 5-min at 4°C) and the supernatant was transferred to a vial from 
which 10 μL was injected into the LC-MS/MS system. Metabolites were separated by HPLC 
using a Prevail silica column (150 × 2.1 mm, 5 μm; Grace, Deerfield, IL) with matching guard 
column (4.6 × 25 mm, 5 um). The mobile phase was run under isocratic conditions (500 μL/min) 
and contained acetonitrile (81%) and ammonium formate (15 mM) with 0.1% formic acid. 
Analyses were performed using electrospray ionization in positive-ion mode with multiple 
reaction monitoring of the following transitions: m/z 76.3 > 58.4 for TMAO; m/z 79.2 > 61.4 for 
13
C3-TMAO; and m/z 85.3 > 66.4 for TMAO-d9. Internal standard, 
13
C3-TMAO, was 
synthesized in house from 
13
C3-TMA hydrochloride (SIGMA, St. Louis, MO) using hydrogen 
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peroxide [22]. Briefly, 30% hydrogen peroxide and 33% of 
13
C3-TMA hydrochloride solution 
were mixed (vol:vol = 6:1) and left at room temperature overnight. The mixture was then dried, 
re-suspended in water and tested with LC-MS/MS. Varying levels of TMAO diluted with water 
were used to produce standard curves for urinary TMAO quantification. The curve was 
generated by plotting the peak area ratios versus the concentrations. Standard curves of plasma 
TMAO were constructed by spiking varying levels of TMAO into control plasma. Spiked 
TMAO area ratios (measured TMAO area ratios minus endogenous TMAO area ratio) were 
plotted against the spiked concentrations to generate the standard curves.  
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea 
nitrogen (BUN), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C), and triglycerides were measured on automated chemistry 
analyzer Dimension Xpand Plus (Siemens Healthcare Diagnostics, Deerfield, IL) at the Human 
Metabolic Research Unit Clinical Chemistry Lab at Cornell University; serum and red blood cell 
folate were measured microbiologically as previous described [13]. 
Choline acetyltransferase (ChAT) transcript abundance 
Quantitative real-time RT-PCR was carried out to analyze the expression of ChAT in 
placental tissues. The RNA extraction, reverse transcription and real-time PCR procedures were 
as previously described [23]. Forward and reverse primers for ChAT were: 5’-
TGGACATGATTGAGCGCTGC-3’ and 5’ –CGTTCTTGCTGTAGCCTCCG-3’, respectively. 
Data are expressed as fold-change of the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH).  
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Statistical Analysis 
 Forty-seven women (21 nonpregnant, 26 pregnant) finished the study and were included 
in the statistical analysis. With the exception of three pregnant women at wk-12, data were 
available for every time point (wk-0, 3, 6, 9, 10 and 12 for blood; wk-0, 6, 9 and 12 for urine). 
For wk-12, three pregnant women (1 in 480 mg choline/d group; 2 in 930 mg choline/d group) 
delivered during the final week of the study.  For these participants, the maternal blood sample 
obtained at delivery was used.  
Plots and histograms of the residuals were used to assess normality and variance 
homogeneity. Data that deviated from the normal distribution (i.e., plasma betaine, plasma 
DMG, serum sarcosine, urinary choline, urinary betaine, urinary DMG, urinary sarcosine and 
urinary homocysteine) were logarithmically transformed to achieve normality and the 
transformed data were used in subsequent analyses.    
To test for baseline (wk-0) differences in the dependent variables between pregnant, 
nonpregnant women and choline intake groups, a two-way ANOVA (choline intake and 
pregnancy) was performed.  
To delineate the impact of pregnancy on the dependent variables through time, a mixed 
linear model was constructed for each dependent variable. As pregnancy is a physiologic state, 
not a treatment, baseline (wk-0) measures of the dependent variables were included as a data 
point. Pregnancy, continuous time (e.g., wk-0, 3, 6, 9, 10 and 12 for plasma variables) and their 
interaction were included as fixed effects; sample ID was included as a random effect. In the 
initial analysis, choline intake and its interactions with pregnancy and continuous time were also 
included as fixed effects; however, no three-way (choline intake x pregnancy x time) or two-way 
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(choline intake x pregnancy) interactions were detected.  Thus, choline intake was not included 
in the final model.  
To delineate the impact of choline intake on the dependent variables, a mixed linear 
model was constructed for each dependent variable after grouping by pregnancy state. As 
baseline (wk-0) measures may influence the response to choline treatment, measures of the 
dependent variables at wk-0 were included as a covariate. Choline intake, continuous time (e.g., 
wk-3, 6, 9, 10 and 12 for plasma variables) and their interaction were included as fixed effects; 
sample ID was included as a random effect; wk-0 measure was included as a covariate.  
Candidates for entry as covariates into both GLMs were age, BMI, and serum folate at 
wk-0. The covariates not achieving a statistical significance of P ≤ 0.05 were removed from the 
models in a stepwise manner.  
To test for differences in the plasma and urinary TMAO, a two-way ANOVA (choline 
intake and pregnancy) was performed with the change through time (wk-12 minus wk-0) as the 
dependent variable and choline intake, pregnancy as well as the baseline (wk-0) measure as the 
independent variables.  To test for differences in the placental and fetal dependent variables, a 
one-way ANOVA (choline intake) was performed. Paired t-tests were also performed to compare 
maternal (at delivery) and fetal corresponding variables.   
The data were analyzed using SPSS software (version 19; SPSS Inc, Chicago, IL). 
Differences were considered to be significant at P ≤ 0.05. Data are presented as means ± SD for 
the dependent variables (unless noted otherwise).
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RESULTS 
Subject characteristics and baseline (wk-0) measures 
Twenty-six third trimester pregnant women and 21 nonpregnant women successfully 
completed the feeding study.  The characteristics and baseline (wk-0) measures of the final study 
group stratified by pregnancy and choline intake group assignment are shown in Table 2. The 
ethnic distribution across the choline intake groups was balanced and reflected the region from 
which the women were recruited. The self-report prepregnancy BMI of pregnant women did not 
differ from nonpregnant women (P = 0.9). The weights of nonpregnant women were maintained 
within ± 8% of initial values. For pregnant women, the average weight gain from wk-0 to wk-12 
of the study was 6.3 ± 2.3 kg (13.9 ± 5.1 lb) and did not differ (P = 0.8) between choline intake 
groups. 
Indicators of liver function (serum ALT and AST) and kidney function (serum BUN) 
were within normal ranges at baseline (Table 1) and throughout the study for all participants 
(data not shown). Serum total cholesterol, LDL-C, HDL-C and triglycerides were 1.3-2.4 times 
higher (P < 0.001) among third trimester pregnant versus nonpregnant women.  Serum folate and 
RBC folate were well above levels associated with deficiency (> 3 ng/mL for serum folate and > 
140 ng/mL for RBC folate) with greater concentrations among pregnant women (P < 0.01) due 
to consumption of a prenatal vitamin containing folic acid by 85% of the pregnant women before 
the onset of the study.   
At baseline, plasma free choline tended to be higher (19%; P = 0.09) while plasma 
betaine, plasma DMG, serum sarcosine, serum homocysteine and serum methionine were 57%, 
44%, 45%, 43% and 15% lower (P < 0.05) respectively among third trimester pregnant versus 
nonpregnant women. Urinary free choline excretion was higher (P < 0.001) among pregnant 
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women and was closely associated (Pearson’s coefficient r = 0.6; P = 0.004) with plasma total 
cholesterol. Plasma TMAO did not differ between pregnant and nonpregnant women (P = 0.5) 
but was lower (P = 0.025) in the women assigned to the high choline intake group. No 
differences (P > 0.2) in urinary TMAO were detected between assigned choline intake groups 
and/or between pregnant and nonpregnant women. 
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TABLE 2 
Baseline (wk-0) measures of clinical and biochemical variables in nonpregnant and third trimester pregnant women randomized to 480 or 930 
mg choline/d
1,2
 
 Nonpregnant women, n = 21  Pregnant women, n = 26 
Variables 480 mg/d 930 mg/d All  480 mg/d 930 mg/d All 
Age (y) 29 (21 - 37) 29 (23 - 40) 29 (21 - 40)  29 (25 - 33) 28 (22 - 34) 28 (22 - 34) 
Ethnicity        
African American (N) 1 1 2  0 1 1 
Asian  (N) 0 1 1  1 2 3 
Caucasian (N) 7 6 13  9 7 16 
Latino (N) 2 2 4  2 2 4 
Other (N) 1 0 1  1 1 2 
Gestational age (week) ------- ------- -------  27 (26-29) 27 (26-28) 27 (26-29) 
Prepregnant BMI (kg/m
2
)  23.7 (19.6-27.3) 23.5 (18.2-29.8) 23.6 (19.6-29.8)  23.6 (20.2-31.9) 23.7 (19.9-29.8) 23.6 (19.9-31.9) 
Serum ALT (U/L) 33 ± 8 30 ± 5.5 31 ± 6.8  36 ± 14 30 ± 7.2 33 ± 11 
Serum AST (U/L) 18 ± 6 17 ± 4 18 ± 5  21 ± 7 18 ± 5 20 ± 6 
Serum BUN (mg/dL) 10 ± 3 11 ± 4 11 ± 3   7 ± 2 7 ± 2 7 ± 2 
c
 
Serum cholesterol (mg/dL) 169 ± 34 160 ± 34 164 ± 33   259 ± 31 238 ± 33 249 ± 33
 c
 
Serum HDL-C (mg/dL) 57 ± 11 61 ± 13 59 ± 12  77 ± 22 75 ± 11 76 ± 17
 c
 
Serum LDL-C (mg/dL) 98 ± 30 91 ± 18 95 ± 23  149 ± 24 142 ± 35 146 ± 29
 c
 
Serum triglycerides (mg/dL) 81 ± 29 55 ± 18 
*
 68 ± 27  176 ± 55 139 ± 34 
*
 158 ± 49
 c
 
Plasma choline (μmol/L) 6.2 ± 1.6 6.1 ± 1.6 6.2 ± 1.6  6.5 ± 1.1 7.4 ± 2.0 7.0 ± 1.7 
Plasma betaine (μmol/L) 22 ± 10 28 ± 10 25 ± 10  11 ± 3 12 ± 5 11 ± 4 c 
Plasma DMG (μmol/L) 2.5 ± 2.3 2.2 ± 1.2 2.3 ± 1.8  1.2 ± 0.5 1.5 ± 0.6 1.3 ± 0.6 a 
Serum sarcosine (μmol/L) 1.0 ± 0.3 1.2 ± 0.5 1.1 ± 0.4   0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.2 c 
Serum Hcy (μmol/L) 7.0 ± 2.0 6.4 ± 0.8 6.7 ± 1.5  4.2 ± 1.0 3.5 ± 0.6 3.8 ± 0.9 c 
Serum methionine (μmol/L) 26 ± 3.9 26 ± 3.1 26 ± 3.4  22 ± 1.8 22 ± 1.8 22 ± 1.8 c 
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Plasma TMAO (μmol/L) 2.5 (0.3 - 10.8)  1.2 (0.4 - 5.6) * 1.8 (0.3 - 10.8)  2.5 (0.5 - 15.7)  1.1(0.2 - 5.8) * 1.8(0.2 - 15.7) 
Serum folate (ng/mL) 20 ± 8 18 ± 7 19 ± 7   29 ± 10 30 ± 18 30 ± 14
 b
 
RBC folate (ng/mL) 472 ± 137 560 ± 139 518 ± 142  920 ± 190 920 ± 387 920 ± 299 
c
 
Urinary choline (mg/g cr) 1.9 ± 0.7 2.0 ± 0.9 2.0 ± 0.8   9.2 ± 6.4 9.2 ± 5.9 9.2 ± 6.0
 c
 
Urinary betaine (mg/g cr) 8.6 ± 5.7 6.4 ± 2.5 7.5 ± 4.1  15.5 ± 9.6 10.6 ± 3.9 13.1 ± 7.6
 b
 
Urinary DMG (mg/g cr) 3.2 ± 2.0 3.1 ± 1.5 3.2 ± 1.7  3.5 ± 2.4 4.4 ± 1.8 4.0 ± 2.1 
Urinary sarcosine (mg/g cr) 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1  0.4 ± 0.2 0.5 ± 0.4 0.5 ± 0.3
 b
 
Urinary Hcy (mg/g cr) 0.5 ± 0.3 0.5 ± 0.2 0.5 ± 0.3  0.6 ± 0.3 0.7 ± 0.4 0.7 ± 0.3 
Urinary methionine(mg/g cr) 1.6 ± 0.6 1.2 ± 0.4 1.3 ± 0.6   2.7 ± 1.3 3.0 ± 2.0 2.8 ± 1.7
 c
 
Urinary TMAO (mg/g cr) 9.9 (3.6 - 18.7) 11 (2.3 - 23) 10.5 (2.3 - 23)  12 (1.3 - 47) 7.4 (1.7 - 26) 9.6 (1.3 - 47) 
1
Data are presented as mean ± SD or (range).   
2
Data were analyzed by 2-way ANOVA; n = 10~13 per group. No significant interactions (P > 0.1) between pregnancy and choline intake were 
detected at baseline for any of the dependent variables. 
Pregnant versus nonpregnant women: 
a
 indicates P ≤ 0.05; b indicates P ≤ 0.01; and c indicates P ≤ 0.001 
480 versus 930 mg choline/d group assignment: 
 *
 indicates P ≤ 0.05  
Abbreviations used: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; DMG, dimethylglycine; HDL-
C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBC, red blood cell; Hcy, total homocysteine; TMAO, 
trimethylamine-N-oxide.   
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Effects of pregnancy on blood and urinary biomarkers of choline metabolism 
Main effects of pregnancy  
Throughout the study, circulating concentrations of choline metabolic biomarkers 
differed between third trimester pregnant and nonpregnant women. On average, third 
trimester pregnant women had 30% higher (P < 0.001) plasma free choline, 55% lower (P < 
0.001) plasma betaine, 38% lower (P < 0.001) plasma DMG, 49% lower (P < 0.001) serum 
sarcosine, 33% lower (P < 0.001) serum homocysteine, and 13% lower (P < 0.001) serum 
methionine than nonpregnant women (Table 3).  
Urinary excretion of biomarkers of choline metabolism also differed between third 
trimester pregnant and nonpregnant women. On average, third trimester pregnant women 
excreted 3.3 times more free choline (P < 0.001), 1.6 times more betaine (P = 0.019), 1.4 
times more sarcosine (P = 0.01), 1.4 times more homocysteine (P = 0.004) and 1.7 times 
more methionine (P < 0.001) than nonpregnant women (Table 3).  
Upon stratifying the cohort by choline intake (i.e., 480 or 930 mg choline/d), 
pregnancy affected the choline metabolites (data not shown) in a manner similar to that 
described in the preceding paragraphs.  
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TABLE 3 Estimated marginal means of biomarkers of choline metabolism among 
nonpregnant and third trimester pregnant women throughout the 12-wk study
1,2 
 Pregnancy status 
Variables Nonpregnant women, n = 21 Pregnant women, n = 26 
Plasma choline (μmol/L) 6.3 (5.6 – 6.9) 8.2 (7.6 – 8.7) c 
Plasma betaine (μmol/L) 26 (23 – 31) 12 (10 – 14) c 
Plasma DMG (μmol/L) 2.5 (2.1 – 3.0) 1.6 (1.3 – 1.9) c 
Serum sarcosine (μmol/L) 1.1 (1.0 – 1.3) 0.6 (0.5 – 0.6) c 
Serum Hcy (μmol/L) 6.0 (5.6 – 6.4) 4.0 (3.8 – 4.3) c 
Serum methionine (μmol/L) 26 (25 – 27) 23 (22 – 24) c 
Urinary choline (mg/d) 3.2 (2.3 – 4.4) 10.7 (8.1 – 14.1) c 
Urinary betaine (mg/d) 8.1 (6.1 – 10.8) 12.9 (10.0 – 16.6) a 
Urinary DMG (mg/d) 4.6 (3.4 – 6.1) 4.4 (3.4 – 5.8) 
Urinary sarcosine (mg/d) 0.4 (0.3 – 0.5) 0.5 (0.4 – 0.6) b 
Urinary Hcy (mg/d) 0.5 (0.4 -0.6) 0.7 (0.6 – 0.9) b 
Urinary methionine (mg/d) 2.8 (2.3 – 3.4) 4.7 (4.2 – 5.3) c 
1
Data are presented as geometric mean (95% confidence intervals) throughout the 12-wk 
study 
2
Data were derived by using mixed linear models that tested the effect of pregnancy on the 
dependent variables as described in the text. Pregnant versus nonpregnant women: 
a
 indicates 
P ≤ 0.05; b indicates P ≤ 0.01; and c indicates P ≤ 0.001. No significant interactions (P > 
0.05) between pregnancy and choline intake were detected. 
Abbreviations used: DMG, dimethylglycine; Hcy, total homocysteine.  
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Pregnancy x Time Interactions 
Pregnancy interacted with time (P < 0.05) to influence the response of several 
circulating choline or 1-C metabolites (i.e., free choline, betaine, and homocysteine).  Among 
third trimester pregnant women, circulating concentrations of free choline (P < 0.001; Figure 
2A), betaine (P < 0.001; Figure 2C) and homocysteine (P < 0.001; Figure 3C) increased by 
13-26% from the beginning (wk-0) to the end (wk-12) of the study. In contrast, circulating 
concentrations of free choline (P = 0.9; Figure 2B) and betaine (P = 0.2; Figure 2D) did not 
change among nonpregnant women and homocysteine decreased (P < 0.001; Figure 3D) by 
16%. The effect of pregnancy on the trajectory of these metabolites during the second half of 
gestation is consistent with previous prospective studies [24, 25]. The increase in plasma free 
choline throughout the third trimester of pregnancy may be due to enhanced de novo choline 
synthesis, a reaction catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT). 
PEMT contains estrogen response elements and its expression is induced by estrogen [26] 
which rises throughout gestation. It also is worth noting that although plasma betaine and 
serum homocysteine rise throughout the third trimester, both variables remain lower (P < 
0.001) than concentrations observed in nonpregnant control women.  
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Figure 2 legend 
Estimated marginal means with 95% confidence intervals of plasma free choline, betaine and 
DMG among third trimester pregnant (A, C, E; n = 26) and nonpregnant women (B, D, F; n = 
21) consuming 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) 
or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12-wk. 
All participants were included in the analysis, and the plotted data were estimated by using 
mixed linear regression models for third trimester pregnant and nonpregnant women 
separately. Wk-0 for pregnant women is wk-27 gestation. Different superscript letters 
indicate that the choline metabolite differed (P < 0.05) between the choline intake groups; 
superscript 
#
 indicates that the choline metabolite tended to differ (P = 0.08) between the 
choline intake groups. Among pregnant women, plasma free choline (P < 0.001) and betaine 
(P < 0.001) increased throughout the 12-wk study; no effect of time (P ≥ 0.2) was observed 
for these metabolites among nonpregnant women.  
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Figure 3 legend 
Estimated marginal means with 95% confidence interval of serum sarcosine, homocysteine 
(Hcy) and methionine (Met) among third trimester pregnant (A, C, E; n = 26) and 
nonpregnant women (B, D, F; n = 21) consuming 480 mg choline/d (n = 13 for pregnant 
group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 
for nonpregnant group) for 12-wk. All participants were included in the analysis, and the 
plotted data were estimated by using mixed linear regression models for third trimester 
pregnant and nonpregnant women separately as described in the text. Wk-0 for pregnant 
women is wk-27 gestation. Different superscript letters indicate that the choline metabolite 
differed (P < 0.05) between the choline intake groups; superscript 
#
 indicates that the choline 
metabolite tended to differ (P = 0.07) between the choline intake groups. Serum 
homocysteine increased throughout the 12-wk study among third trimester pregnant women 
(P < 0.001) but decreased among nonpregnant women (P < 0.001).  
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Effects of choline intake on blood and urinary biomarkers of choline metabolism 
Third trimester pregnant women 
Consumption of 930 mg choline/d yielded 13% higher (P = 0.021) plasma choline 
(Figure 2A), 25% higher (P = 0.016) plasma betaine (Figure 2C), 25% higher (P = 0.012) 
plasma DMG (Figure 2E), and 14% higher (P = 0.07) serum sarcosine (Figure 3A) compared 
to consumption of 480 mg choline/d. Choline intake did not affect serum homocysteine (P = 
0.9; Figure 3C) or serum methionine (P = 0.3; Figure 3E).  
Choline intake did not affect urinary excretion of free choline (P = 0.3; Figure 4A), 
betaine (P = 0.9; Figure 4C), or DMG (P = 0.1; Figure 4E). However, consumption of 930 
mg choline/d yielded 46% higher (P = 0.029) urinary sarcosine (Figure 5A) and 37% higher 
(P = 0.02) urinary methionine (Figure 5E) compared to consumption of 480 mg choline/d.  
Urinary homocysteine also tended to be higher (45%, P = 0.06) in the 930 versus 480 mg 
choline/d intake group (Figure 5C).  These data collectively imply that a higher maternal 
choline intake enhances the metabolic flux of the methionine cycle, which generates both 
methionine and homocysteine.    
Nonpregnant women 
Consumption of 930 mg choline/d yielded 11% higher (P  = 0.08) plasma choline 
(Figure 2B), 43% higher (P = 0.006) plasma betaine (Figure 2D), 37% higher (P = 0.004) 
plasma DMG (Figure 2F), and 46% higher (P = 0.004) serum sarcosine (Figure 3B) 
compared to consumption of 480 mg choline/d. Choline intake did not affect serum 
homocysteine (P = 0.2; Figure 3D) or serum methionine (P = 0.5; Figure 3F). 
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Choline intake did not affect urinary excretion of free choline (P = 0.8; Figure 4B), 
betaine (P = 0.6; Figure 4D), sarcosine (P = 0.3; Figure 5B), homocysteine (P = 0.7; Figure 
5D), or methionine (P = 0.4; Figure 5F). However, consumption of 930 mg choline/d yielded 
42% higher (P = 0.005) urinary DMG (Figure 4F) compared to consumption of 480 mg 
choline/d. 
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Figure 4 legend 
Estimated marginal means with 95% confidence intervals of urinary free choline, betaine and 
DMG among third trimester pregnant (A, C, E; n = 26) and nonpregnant women (B, D, F; n = 
21) consuming 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) 
or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12-wk. 
All participants were included in the analysis, and the plotted data were estimated by using 
mixed linear regression models for third trimester pregnant and nonpregnant women 
separately as described in the text. Wk-0 for pregnant women is wk-27 gestation. Different 
superscript letters indicate that the choline metabolite differed (P < 0.05) between the choline 
intake groups. 
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Figure 5 legend 
Estimated marginal means with 95% confidence intervals of urinary sarcosine, homocysteine 
(Hcy) and methionine (Met) among third trimester pregnant (A, C, E; n = 26) and 
nonpregnant women (B, D, F; n = 21) consuming 480 mg choline/d (n = 13 for pregnant 
group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 
for nonpregnant group) for 12-wk. All participants were included in the analysis, and the 
plotted data were estimated by using mixed linear regression models for third trimester 
pregnant and nonpregnant women separately as described in the text. Wk-0 for pregnant 
women is wk-27 gestation. Different superscript letters indicate that the choline metabolite 
differed (P < 0.05) between the choline intake groups; superscript 
#
 indicates that the choline 
metabolite tended to differ (P = 0.06) between the choline intake groups. 
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Effects of pregnancy and choline intake on plasma and urinary TMAO  
At wk-12, plasma TMAO concentration (P = 0.024; Figure 6A) and urinary TMAO 
excretion (P = 0.008; Figure 6B) were higher in the 930 versus 480 mg choline/d intake 
group. However, the difference in plasma TMAO between choline intake groups was mainly 
driven by 3 out of 24 participants. Exclusion of these participants from the statistical analysis 
attenuated the effects of choline intake on plasma TMAO response (2.9 ± 0.5 vs. 2.2 ± 0.4 
μmol/L; P = 0.07). Pregnancy did not alter plasma TMAO or urinary TMAO excretion nor 
did it interact with choline intake to affect TMAO abundance (data not shown; P > 0.1). 
Notably, a broad range of plasma TMAO concentration and urinary TMAO excretion was 
observed at wk-12 with choline intakes of either 480 mg/d (0.7-7.7 μmol/L for plasma 
TMAO; 1.3-129 mg/day for urinary TMAO) or 930 mg/d (0.6-20.3 μmol/L for plasma 
TMAO; 0.2-162 mg/d for urinary TMAO excretion). The large inter-individual variation in 
plasma and urinary TMAO under conditions of controlled dietary intake (choline and 
alternative trimethylamine-containing species) is consistent with individual differences in the 
composition of colonic microflora. As such, the production of TMAO in response to 
increased choline intake is largely a function of the gut microbiome.  
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Figure 6 legend 
Scatter plot of the change (wk-12 minus wk-0) in plasma TMAO concentration (A) and 
urinary TMAO excretion (B) among third trimester pregnant (n = 26) and nonpregnant (n = 
21) women consuming 480 (n = 13 for pregnant group; n = 11 for nonpregnant group) or 930 
(n = 13 for pregnant group; n = 10 for nonpregnant group) mg choline/d for 12-wk. Data 
were analyzed using 2-way ANOVA with the change through time as the dependent variable, 
choline intake, pregnancy as well as the baseline measure (wk-0) as the independent 
variables.  
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Clinical and biochemical measures of placenta and infants at birth 
Three pregnant women delivered within the final week of the study, and the others 
delivered 0 to 24 days after wk-12. The median (range) interval between the end of the study 
and delivery was 10 (-5, 24) days for 480 mg choline/d group, which did not significantly 
differ (Kolmogorov–Smirnov test, P = 0.16) from 4 (-6, 24) days for 930 mg choline/d group.  
The mean gestational week at birth was 40
 
and did not differ between the choline 
intake groups. Twenty-seven percent of the newborns were female and the gender 
distribution between groups was balanced. Key fetal and placental parameters (Table 4) were 
within normal range and did not differ between choline intake groups (P > 0.05).  
Placental choline and betaine concentrations did not differ (P > 0.05) between choline 
intake groups (Table 4). However, the higher maternal choline intake tended to increase 
placental acetylcholine accumulation (P = 0.089). To further elucidate the effects of maternal 
choline intake on acetylcholine metabolism, we examined the mRNA abundance of ChAT, 
which catalyzes the synthesis of acetylcholine from choline. We found that transcript 
abundance was elevated (P = 0.022) in the 930 mg choline/d intake group suggesting that the 
higher maternal choline intake enhances the placental synthesis of acetylcholine which may 
facilitate amino acid transport, cellular differentiation and parturition [27, 28]. DMG was not 
detected in the placental tissue. 
Consistent with previous reports [29, 30], cord plasma choline was 4.4 times higher 
(35 ± 10 vs. 8 ± 2 μmol/L; P < 0.001) and cord plasma betaine was 3 times higher (30 ± 7 vs. 
10 ± 5 μmol/L; P < 0.001) than maternal plasma concentrations at delivery. However, in 
contrast to prior work showing higher circulating DMG in cord versus maternal plasma [29-
31], we found 29% lower circulating DMG in cord versus maternal plasma (2.0 ± 1.0 vs. 2.8 
± 1.0 μmol/L; P < 0.001).  Notably, maternal plasma DMG in the present study was 
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approximately 56% higher than previous findings [28, 29] possibly due to supplementation of 
the maternal diet with extra choline (i.e, 100 or 550 mg choline/d). 
Although maternal choline intake did not affect concentrations of choline or betaine 
in cord venous plasma (P > 0.1), the higher maternal choline intake (930 versus 480 mg 
choline/d) led to a doubling of cord plasma DMG (P = 0.002; Table 4), the metabolite 
produced when choline is used as a methyl donor. 
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TABLE 4 
Physiological and biochemical parameters of placenta and neonates of pregnant women 
consuming 480 or 930 mg choline/d throughout the third trimester
1,2
 
 Choline Intake 
Variables 480 mg/d, n = 13 930 mg/d, n = 13 
Cesarean section (N) 3 2 
Gestational age at birth (week) 40 (38-41) 40 (39-40) 
Total weight gain throughout the study (kg) 6.4 ± 2.7 6.0 ± 2.2 
Infant gender (female : male) 3 : 10 4 : 9 
Infant birth weight (kg) 3.4 ± 0.4 3.5 ± 0.3 
Infant Length (cm) 50.4 ± 2.0 50.9 ± 2.3 
Infant head circumference (cm) 34.4 ± 1.1 34.3 ± 1.3 
Infant Apgar scores 8.7 ± 0.5; 9 ± 0 8.2 ± 1.4; 8.8 ± 0.6 
Placenta weight (gram) 538 ± 108 529 ± 102 
Placenta length (cm) 15.8 ± 2.3 16.4 ± 1.2 
Placenta width (cm) 19.7 ± 2.7 18.9 ± 1.9 
Placenta depth (cm) 1.6 ± 0.3 1.7 ± 0.4 
Placenta choline (nmol/g tissue) 915 ± 231 941 ± 309 
Placenta betaine (nmol/g tissue) 37 ± 6 37 ± 10 
Placenta acetylcholine (nmol/g tissue) 65 ± 25 88 ± 38 
+
 
Placental ChAT mRNA expression
3
 0.6 ± 0.2 1.4 ± 0.3 
a
 
Cord plasma choline (μmol/L) 37.3 ± 13 32.5 ± 7.5 
Cord plasma betaine (μmol/L) 29.9 ± 6.1 29.4 ± 7.5 
Cord plasma DMG (μmol/L) 1.3 ± 0.5 2.6 ± 0.9 b 
1
Data are presented as mean ± SD or (range).   
2
Data were analyzed with 1-way ANOVA; n = 11-13 per group; 
a
 indicates P ≤ 0.05; b 
indicates P ≤ 0.01; + indicates 0.05 < P < 0.1 
3
Data are presented as the fold-change of the housekeeping gene: glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) 
Abbreviations used: ChAT, choline acetyltransferase; DMG, dimethylglycine 
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DISCUSSION 
This highly controlled feeding study sought to quantify the effects of pregnancy and 
maternal choline intake on maternal and fetal biomarkers of choline metabolism.  Two main 
findings emerged:  (1) pregnancy markedly alters biomarkers of choline metabolism, and (2) 
a higher maternal choline intake increases the use of choline as a methyl donor in both 
maternal and fetal compartments. 
Circulating choline-derived methyl donors are markedly lower in third trimester pregnant 
women as compared to nonpregnant women 
In the present study with controlled choline intake, plasma betaine and DMG were 
40-55% lower in third trimester pregnant than nonpregnant women; a finding that is 
consistent with previous observational reports [24, 29, 30]. We also report for the first time 
that serum sarcosine is 49% lower in third trimester pregnant than nonpregnant women. 
Although hemodilution can contribute to reductions in circulating metabolites during 
pregnancy, expansion of maternal plasma cannot fully explain the lower concentrations of 
these methyl donors. Maternal plasma volume begins to increase at wk-10 gestation and 
expands an average of 45% to provide for the greater circulatory needs of the maternal/fetal 
organs [32]. As such, hemodilution would be expected to yield a 30% reduction in the 
circulating metabolites, not the observed 40-55% reduction. 
An additional explanation is the increased use of choline-derived methyl groups by 
pregnant women. Accelerations in 1-C metabolism transpire during pregnancy to support 
cellular proliferation (e.g., nucleotide biosynthesis) and the establishment of epigenetic 
methylation marks on newly formed cells [33].  Following the use of betaine as a methyl 
donor in the formation of the SAM-precursor methionine, the methyl groups associated with 
DMG and subsequently methylglycine (sarcosine) are used in folate-mediated 1-C 
metabolism for the synthesis of purines, thymidylate, or methionine. 
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Notably, mean serum folate concentrations were elevated (i.e., > 20 ng/mL) among 
the pregnant women at baseline (wk-0) and throughout the study due to their consumption of 
a folic acid containing prenatal vitamin. Thus, although folate and choline are highly 
interrelated, the diminished circulating concentrations of choline-derived methyl donors 
among folate replete pregnant women suggests that extra folate (i.e., folic acid) cannot 
compensate for the higher use of choline as a methyl donor. This may be due to the fact that 
folate is predominately a carrier of methyl groups whereas choline is a source.  
Obligatory losses of urinary choline and betaine were ~2-4 times higher among pregnant 
women 
Pregnant women excreted ~ 4 times more free choline than nonpregnant women at 
baseline (wk-0) and throughout the study.  A greater excretion of free choline has also been 
demonstrated in hyperlipoproteinemic adults [34], a condition that transpires during 
pregnancy [35]. As lipoproteins contain phosphatidylcholine, the greater urinary excretion of 
free choline by pregnant women (relative to nonpregnant women) may be a consequence of 
enhanced uptake and catabolism of lipoprotein-derived phosphatidylcholine in kidney. The 
relatively strong relationship between the urinary excretion of free choline and serum total 
cholesterol at wk-0 (Pearson’s coefficient r = 0.6; P = 0.004) and wk-12 (r = 0.4; P = 0.016) 
is consistent with this metabolic scenario.  
To the best of our knowledge, this is the first report of greater urinary betaine 
excretion in pregnant versus nonpregnant women. Normally, only small amounts of betaine 
are excreted in the urine.  However, during pregnancy, the marked increase in plasma volume 
and glomerular filtration likely contributed to the 2 times greater urinary loss of betaine in 
third trimester pregnant versus nonpregnant women.  
 The markedly diminished circulating concentrations of choline-derived methyl donors 
among pregnant women coupled with their greater urinary excretion of choline and betaine 
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(~13 mg/d when expressed as a choline equivalent) imply that an increment of 25 mg 
choline/d (450 versus 425 mg choline/d) is insufficient to meet the choline demands of 
pregnancy.  
A higher maternal choline intake results in enhanced use of choline as a methyl donor   
A higher choline intake resulted in the greater maternal use of choline as a methyl 
donor as evidenced by the higher concentrations of DMG and sarcosine (intermediates 
formed in the demethylation of choline). The higher concentrations of DMG and sarcosine on 
the higher choline intake level are also consistent with an increased availability of carbons for 
folate-mediated 1-C metabolism. Notably, the higher intake level did not alter the urinary 
excretion of free choline and betaine, which implies that a doubling of the choline AI does 
not exceed the cells capacity to use the extra choline as a methyl donor.  
Although maternal choline intake did not influence neonatal circulating 
concentrations of free choline or betaine, DMG was two times higher in the neonates of 
mothers consuming 930 versus 480 mg choline/d.  As DMG was not detected in the placental 
tissue samples, the DMG in fetal circulation was most likely of fetal origin and generated 
upon the use of choline and/or betaine as methyl donors.  To the best of our knowledge, this 
is the first human study to demonstrate an effect of maternal choline intake on neonatal 
biomarkers of choline metabolism.  
Choline-derived methyl groups are needed for DNA methylation, which is essential 
for developmental processes including genomic imprinting and maintenance of genome 
stability [36]. The increased fetal and maternal use of choline as a methyl donor in the 930 
versus 480 mg choline/d intake group is likely to have functional consequences that are 
mediated through epigenetic mechanisms. The genomic consequences of the higher choline 
intake are currently being explored via measurements of placental and blood leukocyte DNA 
methylation (global and site specific) as well as gene expression analyses.  
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Conclusions and Implications of Study Findings 
 In sum, third trimester pregnant women have substantially lower circulating 
concentrations of choline-derived methyl donors even under folate-replete conditions. 
Coupled with their increased obligatory loss of urinary choline and betaine (~ 13 mg/d as 
choline equivalents), these data suggest that an additional 25 mg choline/d is insufficient in 
meeting the choline demands of third trimester pregnant women.  Moreover, the study 
findings demonstrate that maternal choline intake modifies both maternal and fetal 
biomarkers of choline metabolism with evidence of greater use of choline as a methyl donor 
on a higher choline intake.
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CHAPTER 3 
Pregnancy alters choline metabolism in women consuming methyl-d9-choline 
ABSTRACT   
Background: Little is known about choline metabolism in human pregnancy.  
Objective: This study sought to test the hypothesis that pregnancy alters the metabolic use of 
orally consumed methyl-d9-choline.  
Design: Healthy third trimester pregnant (n = 26, wk 27 gestation) and nonpregnant (n = 21) 
women consumed ~22% of their total choline intake (480 or 930 mg/d) as methyl-d9-choline 
for the last 6-wk of a 12-wk feeding study.  
Results:  At study-end, a lower (P < 0.001) plasma enrichment ratio of d9-betaine:d9-
phosphatidylcholine (PC) was observed in pregnant vs. nonpregnant women, implying 
preferential partitioning of choline into the CDP-choline pathway relative to betaine 
synthesis. Nonetheless, the use of betaine for methionine synthesis was enhanced in pregnant 
(vs. nonpregnant) women, as suggested by a higher (P < 0.001) plasma enrichment ratio of 
d3-methionine:(d3+d9)-betaine. Pregnant (vs. nonpregnant) women also used more choline 
derived methyl groups for PC synthesis via phosphatidylethanolamine N-methyltransferase 
(PEMT) to support their larger pool size as indicated by a comparable increase in PEMT-PC 
enrichment across the last 3-wk of the study. The hydrolysis of PEMT-PC to free choline was 
also enhanced during pregnancy as suggested by a higher plasma enrichment ratio of d3-
choline:d3-PC (P < 0.001). Notably, d3-PC enrichment increased (P < 0.05) incrementally 
from the maternal to placental to fetal compartment implying a selective transfer of PEMT-
PC to the fetus.   
Conclusions: These data demonstrate, for the first time in humans, that both pathways for PC 
synthesis are elevated in late pregnancy with evidence of preferential transfer of PEMT-PC 
towards the fetus.  
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INTRODUCTION 
Pregnancy is a physiologic state characterized by rapid cellular proliferation and 
accelerated one-carbon metabolism [1, 2], both of which increase the demand for the 
essential nutrient choline. Through the cytidine diphosphate-choline (CDP-choline) pathway, 
choline is used to produce phosphatidylcholine (PC), a constituent of all cellular membranes 
and a requisite for tissue expansion. Through its oxidation to betaine, choline serves as a 
methyl donor in one-carbon metabolism and is used to synthesize methionine and S-
adenosylmethionine (SAM), the principal methyl donor in mammalian cells. Notably, a main 
consumer of SAM is phosphatidylethanolamine N-methyltransferase (PEMT), which 
catalyzes the denovo biosynthesis of PC (and choline) from phosphatidylethanolamine (PE).   
Dietary recommendations for choline, in the form of an adequate intake (AI), were 
established by the Institute of Medicine (IOM) for the first time in 1998 [3].  The AI of 450 
mg choline/d for pregnant women is only slightly higher than the AI of 425 mg choline/d for 
nonpregnant women, and may not be sufficient in meeting the demand for choline during late 
pregnancy [4].  Specifically, in a 12-wk controlled feeding study conducted by our research 
group, third trimester pregnant women consuming a level of choline intake approximating the 
AI (i.e. 480 mg choline/d) exhibited depletion of choline derived methyl donors as compared 
to nonpregnant women with an equivalent choline intake [4]. In addition, consumption of 930 
mg choline/d partially normalized circulating concentrations of choline derived methyl 
donors [4], increased the use of choline as a methyl donor in maternal and fetal derived 
tissues [4, 5], and yielded lower circulating concentrations of the stress hormone cortisol in 
fetal cord blood [5]. 
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In our study by Yan et al [4], pregnant and nonpregnant women consumed ~22% of 
their total choline intake (either 480 or 930 mg choline/d) as methyl-d9-choline during the 
last 6 wk of the 12 wk study. As such, the present study seeks to extend this work by 
employing stable isotope methodology to quantify the effect of pregnancy and choline intake 
on the metabolic fate of methyl-d9-choline.   
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STUDY PARTICIPANTS AND METHODS 
Study participants  
Healthy third trimester singleton pregnant women (gestational wk 26-29) aged ≥ 21 y 
and nonpregnant women (n=21) were recruited from the Ithaca, NY area from January 2009–
October 2010 as described by Yan et al [4]. During the screening phase, all study volunteers 
completed a health history and questionnaire and provided a blood sample for blood 
chemistry profiling and a complete blood count. Entry into the study was contingent upon (i) 
good health status (i.e., no chronic diseases, normal kidney and liver function, and non-
anemic), (ii) no drug or alcohol use, and (iii) willingness to comply with study protocol [4].  
Additional inclusion and exclusion criteria were detailed previously [4].  
The study protocol was reviewed and approved by the Institutional Review Board for 
Human Study Participant Use at Cornell University and at the Cayuga Medical Center (the 
hospital where pregnant participants delivered their babies; Ithaca, NY). Written informed 
consent was obtained from all participants prior to their entry into the study.  
Study Design, Diet, and Supplements 
Design 
This was a 12-wk controlled feeding study in which pregnant women (n = 26; wk 26-
29 gestation) and nonpregnant women were randomized to consume either 480 (~ choline AI) 
or 930 mg choline/d. The total choline intake was obtained from the diet (380 mg/d) plus 
supplemental choline chloride (100 mg choline/d for the 480 mg/d intake level; 550 mg 
choline/d for the 930 mg/d intake level). During the last 6 wk of the 12 wk study, ~22% of 
their total choline intake was consumed as supplemental methyl-d9-choline (100 or 200 mg 
choline/d). For the period between completion of the 12-wk study and delivery of the infant, 
pregnant women who had not yet delivered continued to consume their assigned choline 
supplement. Maternal blood (wk 9, 10 and 12) and urine (wk 9 and 12) were collected 
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throughout the feeding phase of the study; a maternal blood sample, placenta tissue and cord 
blood were obtained at delivery [4, 5].   
Diet 
Throughout the 12 wk study, participants consumed a 7-day cycle menu as detailed 
previously [4]. The study diet provided a total of 380 mg choline/d: 236 mg were derived 
from lipid soluble forms and 142 mg were derived from water-soluble forms [4]. The diet 
also provided 100 mg betaine/d. Food was prepared in the Francis A. Johnston and Charlotte 
M. Young Human Metabolic Research Unit (HMRU) at Cornell University. Study 
participants consumed at least one meal/d at the on-site location (i.e., HMRU) during the 
week under the supervision of study personnel; all other food and beverages were provided as 
take-aways, and study participants were required to verify consumption of each food item by 
completing a daily checklist provided by the investigators.   
Supplements 
To achieve the target choline intakes of 480 or 930 mg/d, unlabeled choline 
supplementation prepared with commercially available choline chloride (Balchem, New 
Hampton, NY) was consumed for the first 6 wk. During the last 6-wk of the study (wk 6-12), 
participants obtained ~22% of the their target choline intake (100 or 200 mg choline/d) 
through deuterium labeled choline supplementation prepared from commercial available 
methyl-d9-choline (Cambridge Isotope Laboratories Inc, Andover, MA). Specifically, in the 
480 mg choline/d intake group, choline was derived from the diet (380 mg/d), and a single 
bolus of methyl-d9-labeled supplemental choline chloride (100 mg/d). In the 930 mg 
choline/d intake group, choline was derived from the diet (380 mg/d), and a single bolus of 
unlabeled choline chloride (350 mg/d) mixed with the methyl-d9-labeled choline chloride 
(200 mg/d). Choline supplements were prepared by study personnel as detailed previously 
[4].  
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In addition to the supplemental choline, a prenatal multivitamin (Pregnancy Plus, 
Fairhaven Health, LLC) and docosahexaenoic acid (DHA; 200 mg, Neuromins, Nature's Way 
Products) were provided daily, and a potassium and magnesium supplement (General 
Nutrition Corp) was provided three times per week.  Supplements were consumed under the 
supervision of study personnel at the on-site meal; otherwise, supplements were provided in 
plastic bags along with take-away meals and participants were instructed to consume the 
supplements with a meal of their choice.   
Compliance 
Overall, the study protocol was well tolerated with 92% of the participants 
completing the study regimen (21 of 22 nonpregnant women, 26 of 29 pregnant women). 
Among 26 pregnant women completing the regimen, twenty-two completed the 12 wk study 
and four women completed 10 wk study (due to early delivery). Additional reasons for 
stopping the study included nausea, food dislikes, and personal challenges. The detailed flow 
of study participants through the screening and intervention phases has been reported 
previously [4].  
Sample collection and processing 
Fasting maternal blood samples throughout the 12-wk study were collected into 
serum separator gel and clot-activator tube (SST Vacutainer; Becton, Dickinson and 
Company) and EDTA coated tubes (Vacutainer). Serum and plasma were obtained and stored 
at -80 °C as previously described [4, 6, 7]. 24-h urine samples were collected throughout the 
12-wk study and were processed and stored at -80 °C as described previously [4].  
Maternal delivery blood samples were collected into EDTA coated tubes at the 
hospital within 24 h before delivery. Cord venous blood samples were also collected into 
EDTA-coated tubes at the time of delivery. Maternal delivery blood and cord venous blood 
were processed for plasma and stored at -80 °C. In addition, the placenta was obtained at 
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delivery, processed at the hospital within 90 min of delivery, and stored at -80 °C as 
previously described [4, 5].  
Measurements of plasma, urinary, and placental choline metabolites 
Plasma and placental tissue PC (d0, d3, d6, and d9) and SM (d0, d3, d6, and d9) were 
extracted and quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
as described by Koc et al [8] with modifications based on our instrumentation [9]. Ions with 
m/z ratio of 184 were monitored for unlabeled metabolites (d0-PC and d0-SM) and ions with 
m/z ratios of 187, 190, and 193 were monitored for d3 labeled metabolites (d3-PC and d3-
SM), d6 labeled metabolites (d6-PC and d6-SM), and d9 labeled metabolites (d9-PC and d9-
SM), respectively.  
Plasma, placental tissue, and urinary free choline (d0, d3, d6, and d9), betaine (d0, d3, 
d6, and d9), and dimethylglycine (d0, d3, and d6) were extracted and quantified by LC-
MS/MS according to the method of Holm et al [10] with modifications based on our 
instrumentations [4, 9]. The ions with m/z ratios monitored for each metabolite was as 
following: d0-choline, 104  60; d3-choline, 107  63; d6-choline, 110  66; d9-choline, 
113  69; d0-betaine, 118  59; d3-betaine 121  62; d6-betaine, 124  65; d9-betiane, 
127  68; d0-DMG, 104  58; d3-DMG, 107  61; d6-DMG, 110  64.  
Serum and urinary sarcosine (d0 and d3) and methionine (d0 and d3) were extracted 
and quantified by GC-MS as described previously [11, 12]. 
Urinary S-adenosylmethionine (d0 and d3) was extracted and quantified by LC-
MS/MS as described by Kim et al [13] with modifications based on our instrumentation [5]. 
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Rationale for using methyl-d9-choline as a tracer 
  As shown in Figure 1, the choline tracer used in the present study, methyl-d9-choline 
is labeled with deuterium on all three methyl groups. Therefore, it traces the fate of the intact 
molecule (d9-choline metabolites) and of its methyl groups (predominately d3-choline 
metabolites) [9]. The administered methyl-d9-choline can enter the CDP-choline pathway to 
produce d9-PC or it can be oxidized to d9-betaine, which donates a methyl group to 
homocysteine, producing d6-DMG and d3-methionine. D3-methionine serves a precursor to 
d3-SAM, which can be used by PEMT to sequentially methylate phosphatidylethanolamine 
(PE) forming d3-PC, d6-PC, and small amounts of d9-PC [4]. Under the current labeling 
strategy, the amount of PEMT derived d9-PC (~0.02% of plasma total PC) is lower than the 
detection limits (~ 0.1% of plasma total PC). Therefore, we consider that all the detected d9-
PC is derived from CDP-choline pathway. Hydrolysis of d3-PC will generate d3-choline as 
well as d3-betaine, d3-methinone, d3-DMG, and d3-sarcosine when d3-choline is used as a 
methyl donor. 
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Figure 1 legend 
Deuterium labeled methyl-d9-choline traces the distribution of orally consumed choline and 
its methyl groups. Black circles indicate deuterium labeled methyl groups; white circles 
indicated unlabeled methyl groups. Abbreviations: DMG, dimethylglycine; SAR, sarcosine; 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; SAH, S-adenosylhomocysteine; 
SAM, S-adenosylmethionine; SM, sphingomyelin; PEMT, phosphatidylethanolamine N-
methyltransferase. 
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Isotopic enrichment [labeled metabolite/(labeled + unlabeled metabolite)] was 
examined in blood, urine, and placental tissue to monitor the flow of dietary choline (d9-
choline metabolites) and its methyl groups (d3-choline metabolites) through choline 
metabolic pathways. The isotopic enrichment percentage was calculated using the peak area 
under the chromatography curve of the labeled metabolite divide by the total area of all 
isotopomers of the metabolite. For example, the enrichment percentage of d3-PC = peak area 
of d3-PC / peak area of (d0+d3+d6+d9)-PC × 100%. The enrichment of d3-PC indicates the 
proportion of PEMT derived d3-PC in plasma total PC pool. Metabolite enrichment ratios 
were examined as indicators of orally consumed choline use through a specific portion of a 
pathway (enrichment of product/ enrichment of precursor) or its partitioning between 
pathways.  
In addition, based on the principle of Mass Isotopomer Distribution Analysis (MIDA) 
[14, 15], we can use the mass spectra abundances of d0, d3, d6, and d9 choline isotopomers 
to delineate the effect of pregnancy and choline intake on the activity of PEMT mediated PC 
synthesis (which mainly occurs in the liver).  For this purpose, the equation defined by Foster 
et al [16] for calculating the fractional synthesis rate (i.e., the fraction of total PC which is 
replaced by PEMT-PC using choline derived methyl groups) was modified to accommodate 
the longitudinal design of the present study as depicted in Equation 1:   
The incremental labeling of plasma PC pool with PEMT-PC between time points 1 and 2 
= 
                  
(               )  
                                                                                  (1) 
EPEMT_t1 and EPEMT_t2 were the plasma enrichment of PEMT-PC (d3+d6-PC) at time 
point 1 and 2; ESAM_t1 and ESAM_t2 were the hepatic enrichment of d3-SAM at time point 1 and 
2. Equation 1 was further modified to adjust for differences between the weeks in PC pool 
size as depicted in Equation 2:  
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The incremental labeling of plasma PC pool with PEMT-PC between time points 1 and 2  
 = 
          
         
         
⁄           
(               )  
                                                      (2) 
PoolPC_t1 and PoolPC_t2 were the concentrations of plasma PC at time point 1 and 2. 
The calculated values from equation 2 represent the incremental labeling of the plasma PC 
pool with PEMT-PC and indicate the flux of choline derived methyl groups through the 
PEMT pathway.      
This strategy requires an estimation of the hepatic enrichment of the precursor 
molecule, d3-SAM. The hepatic enrichment of d3-SAM can be calculated using the plasma 
enrichment of its products, d3-PC and d6-PC, which were quantified in the present study.  
The equation for the calculation of d3-SAM is as follows [15]:  
Hepatic d3-SAM enrichment = 
      
              
                                            (3)                                                                            
Ed3-PC and Ed6-PC were the quantified enrichment of d3-PC and d6-PC. In our study, 
the calculated hepatic d3-SAM enrichment was highly correlated (Pearson’s correlation 
coefficient r = 0.74, P < 0.001) with the measured urinary d3-SAM enrichment.  
 
Statistical analysis 
Twenty-one nonpregnant and twenty-two third trimester pregnant women completed 
the 12-wk study and were included in the statistical analysis.  
Plots and histograms of the residuals were used to assess normality and variance 
homogeneity of dependent variables. All dependent variables were fit the assumption of the 
analysis of variance model. 
To delineate the effect of pregnancy on study-end (wk 12) concentrations of the 
choline metabolites and their enrichment, a 2-factor ANOVA (choline intake and pregnancy) 
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including the interaction term (pregnancy × choline intake) was conducted. If the interaction 
term was significant at P ≤ 0.05, data were stratified by choline intake, and the effect of 
pregnancy on metabolite concentrations was examined for women consuming 480 or 930 mg 
choline/d, separately. Because pregnancy is a physiologic state, baseline values were not 
entered as covariates into the statistical model.  
To evaluate the main effect of choline intake on the dependent variables at wk 12, we 
conducted a 1-factor ANOVA (choline intake) for pregnant and nonpregnant women, 
separately. In addition, for the choline metabolite concentrations, baseline (wk 0) values were 
included in the model as a covariate.  
To test for differences in the maternal delivery, placental, and fetal dependent 
variables between choline intake groups, a 1-factor ANOVA (choline intake) was performed. 
The time interval between completion of the 12-wk study and delivery of the infant was 
included as a covariate in the model if it was a significant predictor of the dependent variable. 
Paired t tests were performed to compare corresponding variables in maternal delivery blood, 
placental tissue, and fetal cord blood. 
Data are presented as means ± SEM (unless noted otherwise) and were analyzed by 
SPSS software (version 20; SPSS Inc, Chicago, IL). Differences were considered to be 
significant at P ≤ 0.05, whereas a P < 0.10 was indicative of trends. 
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RESULTS 
Characteristics of study population at the study-end (wk 12) 
Table 1 shows the plasma and urinary choline metabolites and biochemical indices 
related to one-carbon metabolism at study-end (wk 12). Compared to nonpregnant women, 
third trimester pregnant women had 47 % higher (P < 0.001) plasma choline, 61% higher (P 
< 0.001) plasma PC, but lower (11-61%; P < 0.01) circulating concentrations of betaine, 
DMG, sarcosine and methionine. In addition, the obligatory losses of urinary choline and 
betaine were 2 ~ 5 times greater (P ≤ 0.028) among pregnant versus nonpregnant women. 
Among nonpregnant women, consumption of 930 (versus 480) mg choline/d yielded 
higher (29 - 67%, P < 0.02) circulating concentrations of betaine, DMG and sarcosine as well 
as greater excretion of urinary DMG (70%, P = 0.009). Among pregnant women, 
consumption of 930 (versus 480) mg choline/d tended to yield 48% higher plasma betaine (P 
= 0.059), 47% higher plasma DMG (P = 0.057) and 140% greater urinary sarcosine (P = 
0.078).  
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TABLE 1: Blood and urinary concentrations of choline metabolites and biochemical indices related to one-carbon metabolism at study-end (wk 
12) in nonpregnant and third trimester pregnant women consuming 480 or 930 mg choline/d for 12 wks
1
 
 Nonpregnant women, n = 21  Third trimester pregnant women, n = 22 
Variables 480 mg/d 930 mg/d 
3
 All 
2
  480 mg/d 930 mg/d 
3
 All 
2
 
Plasma choline (μmol/L) 5.7 ± 0.4 6.2 ± 0.3 6.0 ± 0.2  8.0 ± 0.5 9.6 ± 0.7 8.8 ± 0.5 *** 
Plasma betaine (μmol/L) 21 ± 2.8 35 ± 3.3 a 28 ± 2.4  12 ± 0.5 18 ± 3.0 # 14 ± 1.4 *** 
Plasma DMG (μmol/L) 2.8 ± 0.8 3.6 ± 0.5 b 3.2 ± 0.4  1.7 ± 0.2 2.5 ± 0.4 # 2.0 ± 0.2 ** 
Serum sarcosine (μmol/L) 0.9 ± 0.1 1.4 ± 0.1 c 1.2 ± 0.08  0.56 ± 0.05 0.65 ± 0.04 0.6 ± 0.03 *** 
Serum methionine (μmol/L) 25 ± 1.2 26 ± 1.2 26 ± 0.8  24 ± 0.9 22 ± 0.7 23 ± 0.6 ** 
Serum homocysteine (μmol/L) 5.6 ± 0.3 5.8 ± 0.3 5.6 ± 0.2  4.6 ± 0.3 4 ± 0.2 4.4 ± 0.2 *** 
Serum folate (ng/mL) 30 ± 2.4 26 ± 1.6 28 ± 1.4  29 ± 2.8 26 ± 2.3 27 ± 1.8 
Plasma PC (μmol/L) 1728 ± 108 1709 ± 70 1718 ± 61  2776 ± 127 2754 ± 188 2766 ± 107 *** 
Plasma SM (μmol/L) 626 ± 47 609 ± 43 617 ± 31  943 ± 53 828 ± 65 891 ± 42 *** 
Urinary choline (mg/g cr) 3.7 ± 1.3 3.8 ± 0.9 3.7 ± 0.8  20.5 ± 5.8 18.7 ± 5.4 19.7 ± 3.8 
***
 
Urinary betaine (mg/g cr) 8.8 ± 2.2 7.4 ± 1.3 8.1 ± 1.2  21 ± 6.1 13 ± 3.2 17.6 ± 3.8 
*
 
Urinary DMG (mg/g cr) 4.0 ± 0.6 6.8 ± 1.1 
b
 5.5 ± 0.7  5.7 ± 1.4 6.8 ± 1.1 6.2 ± 0.9 
Urinary sarcosine (mg/g cr) 0.45 ± 0.06 0.57 ± 0.06 
#
 0.5 ± 0.04  0.5 ± 0.06 1.2 ± 0.44 
#
 0.8 ± 0.22 
Urinary methionine (mg/g cr) 3.0 ± 0.2 2.8 ± 0.3 2.9 ± 0.2  5.9 ± 2.0 4.9 ± 0.6 5.4 ± 1.1 
*
 
Urinary homocysteine (mg/g cr) 0.45 ± 0.04 0.46 ± 0.06 0.46 ± 0.03  0.7 ± 0.06 1.2 ± 0.28 0.9 ± 0.14 
**
 
1
Data are presented as mean ± SEM.  
2
2- way ANOVA (pregnancy, choline intake, and their interactions) was used to compare the concentrations of choline metabolites and 
biochemical indices related to one-carbon metabolism between pregnant and nonpregnant women; n = 19-23 per group; 
#
 indicates 0.05 < P < 
0.1, 
*
 indicates P ≤ 0.05, ** indicates P ≤ 0.01, *** indicates P ≤ 0.001 
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3
1-way ANOVA (choline intake) was used to compare the concentrations of choline metabolites and biochemical indices related to one-carbon 
metabolism between choline intake groups for pregnant women or nonpregnant women, separately; wk 0 measures of concentrations were 
included as covariates in the tests; n = 9-12 per group; 
#
 indicates 0.05 < P < 0.1, 
a
 indicates P ≤ 0.05, b indicates P ≤ 0.01, c indicates P ≤ 0.001 
Abbreviations used: DMG, dimethylglycine; PC, phosphatidylcholine; SM, sphingomyelin; LPC, lysophosphatidylcholine 
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Effects of maternal choline intake and pregnancy on the isotopic enrichment and enrichment 
ratio of choline metabolites  
  At study-end, labeled choline metabolites were detected at acceptable signal-to-noise 
ratios in blood and urine samples including d3-choline, d9-choline, d3-betaine, d9-betaine, 
d3-DMG, d6-DMG, d3-sarcosine, d3-methionine, d3-SAM, d3-PC, d6-PC, d9-PC, and d9-
SM. The blood and urinary enrichment of the same metabolite was highly correlated 
(Pearson’s correlation coefficient r ≥ 0.7, P < 0.001).  
Main effect of pregnancy 
At the study-end, pregnant women had lower plasma enrichment of d9-choline (P = 
0.02), d6-DMG (P < 0.001), d3-PC (P = 0.005), d6-PC (P = 0.002), and d9-PC (P = 0.07) 
and lower urinary enrichment of d9-choline (P < 0.001), d9-betaine (P < 0.001), and d6-
DMG (P < 0.001) (Table 2). The calculated hepatic enrichment of d3-SAM (P < 0.001) was 
also lower among pregnant versus nonpregnant women. The systemically lower enrichment 
of labeled choline metabolites (e.g., d9-choline) among pregnant women may arise from a 
greater dilution of the labeled d9-choline in the unlabeled choline (d0-choline) and 
phosphatidylcholine (d0-PC) pools, which were approximately 50% higher among third 
trimester pregnant women as compared to nonpregnant women [4].  
In contrast, third trimester pregnant women (versus nonpregnant women) tended to 
have higher (P ≤ 0.06) plasma and urinary enrichment of d3-choline, a derivative of d3-PC 
produced by the PEMT pathway.  Pregnant women also had higher plasma/urinary 
enrichment of d3-betaine (P ≤ 0.013) and d3-DMG (P = 0.01), which are generated when d3-
choline is used as a methyl donor. In addition, the enrichment of serum d3-methionine was 
31% higher (P = 0.022) among pregnant versus nonpregnant women possibly reflecting 
greater synthesis of methionine from the endogenously produced d3-choline. Finally, the 
enrichment of d3-choline, the enrichment ratio of d3-choline:d3-PC (P = 0.001), and the 
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enrichment ratio of d3-betaine:d3-choline (P = 0.08) were higher among pregnant versus 
nonpregnant women, suggesting a greater hydrolysis of PEMT-PC tofree choline, and an 
enhanced use of choline liberated from PEMT-PC for betaine synthesis in late pregnancy.  
The enrichment of PEMT-PC increased to a similar extent among pregnant and 
nonpregnant women: the change in PEMT-PC enrichment did not differ (P > 0.7) between 
pregnant and nonpregnant women from wk 9 to wk 10 (pregnant versus nonpregnant: 1.2 ± 
0.7 versus 1.28 ± 1.1) or from wk 10 to wk 12 (pregnant versus nonpregnant: 1.35 ± 1.0 
versus 1.38 ± 0.8).  Given that (i) the plasma PC pool is ~ 1.5 times greater among pregnant 
versus nonpregnant women; and (ii) enrichment of PEMT-PC changed to a similar extent 
among pregnant and nonpregnant women, these data imply greater use of choline derived 
methyl groups for PC production through the PEMT pathway among third trimester pregnant 
women. These data are consistent with an upregulation of PEMT activity by estrogen [17, 18] 
which rises during the second half of pregnancy [19, 20]. 
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TABLE 2: Blood and urinary enrichment and the enrichment ratios of choline metabolites at study-end (wk 12) in third trimester pregnant and 
nonpregnant women consuming ~ 22% of 480 or 930 mg choline/d as methyl-d9-choline from study wk 6 to wk 12
1
 
 Nonpregnant women, n = 21  Third trimester pregnant women, n = 23 
Variables 480 mg/d 930 mg/d 
3
 All 
2
  480 mg/d 930 mg/d 
3
 All 
2
 
Maternal blood enrichment        
   d9-choline 7.0 ± 0.2  8.5 ± 0.3
 b
  7.7 ± 0.3  6.4 ± 0.3 7.6 ± 0.4
 a
  6.9 ± 0.3
 *
 
   d9-betaine 8.0 ± 0.2  11 ± 0.5
 c
  9.6 ± 0.5  6.7 ± 0.3  8.4 ± 0.4
 b
  7.4 ± 0.3
 ***
 
   d6-DMG 29 ± 0.7  37 ± 1.0
 c
  33 ± 1.0  25 ± 1.0  31 ± 2.0
 b
  27 ± 1.0
 ***
  
   d3-choline 2.3 ± 0.2  2.9 ± 0.1
 b
  2.6 ± 0.1  2.4 ± 0.1 3.4 ± 0.1
 c
 2.8 ± 0.2
 #
 
   d3-betaine 1.5 ± 0.1  1.9 ± 0.1
 b
  1.7 ± 0.1  1.7 ± 0.1 2.4 ± 0.1
 c
  2.0 ± 0.1
 *
 
   d3-sarcosine 
4
 22 ± 0.6 29 ± 0.9
 c
 25 ± 1   21 ± 1 27 ± 1
 b
 24 ± 1 
   d3-methionine 
4
 0.49 ± 0.05 0.67 ± 0.08 
#
 0.58 ± 0.05  0.62 ± 0.07 0.93 ± 0.11
 b
 0.76 ± 0.07
 *
 
   d3-PC 1.03 ± 0.06 1.51 ± 0.09
 c
 1.27 ± 0.08  0.86 ± 0.05 1.25 ± 0.09 
c
 1.03 ± 0.07
 **
 
   d6-PC 0.18 ± 0.01 0.43 ± 0.03
 c
 0.31 ± 0.03  0.13 ± 0.02 0.31 ± 0.04
 c
 0.21 ± 0.03
 **
 
   d9-PC 8.6 ± 0.4 9.9 ± 0.4
 b
 9.3 ± 0.2  8.0 ± 0.4 9.2 ± 0.5
 #
 8.5 ± 0.3
 #
 
   d9-SM 8.7 ± 0.3 10.1 ± 0.3
 b
 9.4 ± 0.3  8.2 ± 0.4 9.4 ± 0.5
 #
 8.7 ± 0.3 
#
 
   Hepatic d3-SAM 
5
 0.152 ± 0.01  0.222 ± 0.01
 c
 0.187 ± 0.01  0.132 ± 0.01  0.191 ± 0.01
 c
 0.157 ± 0.01 
***
 
Maternal blood enrichment ratios       
   d9-betaine : d9-choline 1.14 ± 0.03 1.33 ± 0.03
 c
 1.24 ± 0.03  1.05 ± 0.16  1.10 ± 0.28
 #
  1.07 ± 0.02
 ***
 
   d9-PC : d9-choline 1.23 ± 0.02 1.17 ± 0.02 
#
  1.20 ± 0.02  1.24 ± 0.03  1.20 ± 0.02 1.22 ± 0.02  
   d9-SM : d9-PC 1.01 ± 0.01 1.02 ± 0.01 1.02 ± 0.01  1.02 ± 0.01 1.03 ± 0.01 1.02 ± 0.01 
   d9-betaine : d9-PC 0.93 ± 0.03 1.14 ± 0.04
 c
  1.04 ± 0.04  0.85 ± 0.02  0.92 ± 0.02
 b
  0.88 ± 0.02
 ***
 
   d6-DMG : d9-betaine 3.72 ± 0.11 3.29 ± 0.11
 a
  3.51 ± 0.09  3.67 ± 0.08  3.66 ± 0.09 3.67 ± 0.06 
   d3-met : d3+d9-betaine 0.052 ± 0.01 0.051 ± 0.01  0.051 ± 0.01  0.073 ± 0.01 0.087 ± 0.01  0.079 ± 0.01
 ***
 
   d3-sarcosine : d6-DMG 0.76 ± 0.03 0.77 ± 0.01 0.76 ± 0.02  0.86 ± 0.02 0.89 ± 0.02 0.87 ± 0.01 
***
 
   d3+d6-PC : d9-PC 0.14 ± 0.01 0.20 ± 0.01
 b
  0.17 ± 0.01  0.13 ± 0.01  0.17 ±0.01 
b
  0.15 ± 0.01
 #
  
   d3-choline : d3-PC 2.22 ± 0.11  1.92 ± 0.11
 a
  2.07 ± 0.07  2.80 ± 0.14 2.78 ± 0.15  2.79 ± 0.10 
***
 
   d3-betaine : d3-choline 0.69 ± 0.02 0.67 ± 0.01 0.67 ± 0.01  0.71 ± 0.01 0.70 ± 0.01 0.70 ± 0.01
 #
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Urinary enrichment         
   d9-choline 12.0 ± 0.8 14.3 ± 0.9
 #
 13.2 ± 0.6  9.0 ±0.7 11.3 ± 0.7
 a
 10.0 ± 0.5
 ***
 
   d9-betaine 10.7 ± 0.5 13.6 ± 0.6
 c
 12.1 ± 0.5   7.9 ± 0.6 9.3 ± 0.4
 #
 8.5 ± 0.4
 ***
 
   d6-DMG 35 ± 1.2 41 ± 0.9
 b
 38 ± 1.0  27 ± 1.5  32 ± 1.5
 a
 29 ± 1.2 
***
 
   d3-choline 2.2 ± 0.1 2.6 ± 0.2
 a
 2.4 ± 0.1  2.4 ± 0.1 3.0 ± 0.2
 b
 2.6 ± 0.1
 #
 
   d3-betaine 1.6 ± 0.1 1.8 ± 0.1
 a
  1.7 ± 0.1  1.7 ± 0.1 2.3 ± 0.1
 b
 2.0 ± 0.1
 *
 
   d3-DMG 1.3 ± 0.1 1.4 ± 0.1 1.3 ± 0.1   1.5 ± 0.1 1.7 ± 0.1 1.6 ± 0.1
 **
 
   d3-sarcosine 23 ± 2.3 30 ± 1.9
 a
 27 ± 1.6   21 ± 2.4 29 ± 1.8
 a
 25 ± 1.7 
   d3-met 0.44 ± .07 0.77 ± 0.08
 b
 0.60 ± 0.07    0.55 ± 0.08 0.65 ± 0.05 0.59 ± 0.05 
   d3-SAM 0.58 ± 0.03  0.72 ± 0.05
 a
 0.65 ± 0.03   0.49 ± 0.03  0.70 ± 0.04
 c
 0.58 ± 0.03  
Urinary enrichment ratios        
   d9-betaine : d9-choline 0.89 ± 0.02 0.96 ± 0.04  0.93 ± 0.02  0.87 ± 0.02 0.84 ± 0.04 0.86 ± 0.02
 *
 
   d3-betaine : d3-choline 0.72 ± 0.01 0.71 ± 0.02 0.72 ± 0.01  0.73 ± 0.01 0.75 ± 0.01 0.74 ± 0.01 
*
 
   d6-DMG:d9-betaine 3.4 ± 0.18 3.1 ± 0.13 3.2 ± 0.11  3.53 ± 0.16 3.39 ± 0.09 3.5 ± 0.10 
   d3-DMG:d3-betaine 0.84 ± 0.02 0.75 ± 0.02
 b
 0.79 ± 0.02  0.85 ± 0.03 0.76 ± 0.02
 a
 0.81 ± 0.02 
   d3-met : d3+d9-betaine 0.037 ± 0.007 0.050 ± 0.006 0.044 ± 0.005  0.061 ± 0.01 0.056 ± 0.004  0.059 ± 0.006 
*
 
   d3-sarcosine : d3+6-DMG 0.65 ± 0.07 0.70 ± 0.04 0.67 ± 0.04  0.74 ± 0.08 0.86 ± 0.05 0.79 ± 0.05
 #
 
   d3-SAM : d3-methionine 1.63 ± 0.24  1.08 ± 0.14
 #
 1.37 ± 0.15  1.10 ± 0.16 1.13 ± 0.12 1.11 ± 0.10 
1
Data are presented as mean ± SEM.  
2
2- way ANOVA (pregnancy, choline intake, and their interactions) was used to compare the enrichment or enrichment ratio between pregnant 
and nonpregnant women; n = 19-23 per group; 
#
 indicates 0.05 < P < 0.1, 
*
 indicates P ≤ 0.05, ** indicates P ≤ 0.01, *** indicates P ≤ 0.001 
3
1-way ANOVA (choline intake) was used to compare the enrichment or enrichment ratio between choline intake groups for pregnant women or 
nonpregnant women, separately; n = 9-12 per group; 
#
 indicates 0.05 < P < 0.1, 
a
 indicates P ≤ 0.05, b indicates P ≤ 0.01, c indicates P ≤ 0.001 
4
 Methionine and sarcosine enrichment were obtained in serum whereas the concentrations of other metabolites were obtained in plasma.   
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5
 Hepatic enrichment of d3-SAM was calculated using the plasma enrichment of d3-PC and d6-PC according to the principle of mass 
isotopomer distribution analysis (MIDA) using the equation: hepatic d3-SAM enrichment = d6-PC enrichment/ (d3-PC enrichment + d6-PC 
enrichment) 
Abbreviations used: DMG, dimethylglycine; met, methionine; SAM, S-adenosylmethionine; PC, phosphatidylcholine; SM, sphingomyelin 
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Pregnancy x choline intake interaction 
Pregnancy interacted with choline intake to affect plasma enrichment of d9-betaine (P 
= 0.034).  Plasma d9-betaine enrichment was 16% lower (P = 0.003) among pregnant versus 
nonpregnant women consuming 480 mg choline/d and was 25% lower (P < 0.001) among 
pregnant versus nonpregnant women consuming 930 mg choline/d (Table 2).  In addition, the 
enrichment ratio of d9-betaine:d9-PC was 10% lower (P = 0.022) among pregnant versus 
nonpregnant women consuming 480 mg choline/d and was 19% lower (P < 0.001) among 
pregnant versus nonpregnant women consuming 930 mg choline/d. These data suggest a 
reduced partitioning of choline to betaine synthesis relative to the CDP-choline pathway in 
late pregnancy. In addition, the greater difference (19% versus 10% for d9-betaine:d9-PC) at 
the 930 versus 490 mg choline/d intake level is consistent with greater oxidation of choline 
by nonpregnant (versus pregnant) women on the higher choline intake. Notably, the 
enrichment ratio of d9-betaine:d9-PC in third trimester pregnant women consuming 930 mg 
choline/d was not different from that of nonpregnant women consuming 480 mg choline/d 
(0.92 ± 0.02 vs. 0.93 ± 0.03; P = 0.9) indicating that a higher choline intake is needed by 
third trimester pregnant women to ensure an adequate supply of betaine under conditions of 
enhanced PC production by CDP-choline pathway.  
Main effect of choline intake 
As expected, a higher enrichment of almost all the choline metabolites was observed 
in biological samples collected from pregnant and nonpregnant women consuming 930 
versus 480 mg choline/d (Table 2 and 3).  
Among both pregnant and nonpregnant women, plasma enrichment ratios of d9-
betaine:d9-choline, d9-betaine:d9-PC, and (d3+d6)-PC:d9-PC were higher in the 930 versus 
480 mg choline/d intake group, suggesting that a higher choline intake favors oxidation of 
choline and the use of choline derived methyl groups for PEMT mediated PC synthesis.  
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Among nonpregnant women, consumption of 930 (versus 480) mg choline/d yielded a 
greater (P = 0.033) change of the enrichment of PEMT-PC (d3+d6-PC) between wk 10 and 
wk 12, compared to 480 mg choline/d (1.7 ± 0.8 vs. 1.0 ± 0.6), suggesting that a higher 
choline intake increases PC production through PEMT pathway in nonpregnant women. 
Because PC synthesized through PEMT pathway is enriched with DHA, this finding is 
consistent with our previous observation that the proportion of PC-DHA in total PC molecule 
was higher in nonpregnant women consuming 930 versus 480 mg choline/d (West et al. 
submitted). No effect of choline intake on the change of the enrichment of PEMT-PC 
(d3+d6-PC) was detected among pregnant women.  
It is interesting to note that among nonpregnant women, the plasma enrichment ratio 
of d6-DMG:d9-betaine (P = 0.016), the urinary enrichment ratio of d3-SAM:d3-methionine 
(P = 0.07), d3-DMG:d3-betaine (P = 0.003), and the plasma enrichment ratio of d3-
choline:d3-PC (P = 0.028) were lower in the 930 vs. 480 mg choline/d intake group.  These 
data suggest that although the higher choline intake increased the use of choline as a methyl 
donor, segments throughout the oxidative pathway were affected to a different extent. 
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TABLE 3: Enrichment of choline metabolites in delivery blood, placental tissue, and fetal 
cord blood obtained from pregnant women consuming ~22% of 480 or 930 mg choline/d as 
methyl-d9-choline from study wk 6 till delivery 
1,2
 
 Choline Intake 
Variables 480 mg/d, n = 12 930 mg/d, n = 12 
Maternal delivery blood   
    d9-choline     4.9 ± 0.5 6.6 ± 0.6
 a 
 
    d9-betaine     5.9 ± 0.6  8.4 ± 0.8
 a
 
    d6-DMG     14.5 ± 0.9 19.4 ± 1.3 
b
 
    d3-choline     0.58 ± 0.07  0.87 ± 0.11
 a
 
    d3-PC     2.0 ± 0.2 2.8 ± 0.2 
b
 
    d6-PC     0.12 ± 0.02 0.28 ± 0.03 
c
 
    d9-PC     7.1 ± 0.7 8.8 ± 0.8 
    d9-SM     7.8 ± 0.6 9.1 ± 0.7 
Placental tissue   
    d9-choline     3.3 ± 0.3 4.4 ± 0.4 
a
 
    d9-betaine     4.6 ± 0.4  6.4 ± 0.5 
a
 
    d3-choline     1.0 ± 0.1 1.5 ± 0.1 
b
 
    d3-PC     2.2 ± 0.2 2.9 ± 0.2 
a
 
    d9-PC     3.9 ± 0.4 4.9 ± 0.5 
#
 
    d9-SM     5.0 ± 0.4 5.7 ± 0.5  
Fetal cord blood 
    d9-choline     3.6 ± 0.3 4.5 ± 0.4 
    d9-betaine     4.6 ± 0.4 5.8 ± 0.4 
a
 
    d6-DMG     16.5 ± 1.7 19.4 ± 1.5 
    d3-choline     1.8 ± 0.2 2.7 ± 0.2 
b
 
    d3-PC     3.6 ± 0.2 4.5 ± 0.2 
b
 
    d9-PC     3.0 ± 0.2 3.8 ± 0.3
 #
 
    d9-SM     3.7 ± 0.3 4.3 ± 0.3 
#
 
1
Data are presented as mean ± SEM.  
2
Data were analyzed with 1-way ANOVA (choline intake); n = 9-12 per group; 
#
 indicates 
0.05 < P < 0.1, 
a
 indicates P ≤ 0.05, b indicates P ≤ 0.01, c indicates P ≤ 0.001 
No effect of choline intake on the enrichment ratios within each compartment was detected 
except that the enrichment ratio of d9-betaine:d9-PC was higher in the 930 versus 480 mg 
choline/d intake group in maternal delivery blood (0.96 ± 0.02 versus 0.83 ± 0.04, P = 
0.014). 
Abbreviations used: DMG, dimethylglycine; PC, phosphatidylcholine; SM, sphingomyelin. 
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Comparisons of the enrichment of choline metabolites among delivery blood, placenta, and 
cord blood  
As presented in the Figure 2, the enrichment of d3-choline and d3-PC in the three 
compartments was in the order of maternal delivery blood < placental tissue < fetal cord 
blood (P < 0.001 for any comparisons between two compartments). In contrast, the 
enrichment of d9-PC and d9-SM was in the reverse order of maternal delivery blood > 
placental tissue > fetal cord blood (P < 0.001 for any comparisons between two 
compartments).  
It is also notable that the enrichment of d6-DMG tended to be higher in the cord blood 
compared to maternal blood (P = 0.06). Because DMG is not transferred from the maternal to 
fetal compartment [4], these data imply an active use of choline/betaine derived methyl 
groups in fetal compartment and are consistent with enhanced BHMT activity in human 
infants [21, 22]. 
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Figure 2 legend 
Enrichment of choline metabolites in delivery blood, placental tissue, and fetal cord blood 
obtained from pregnant women consuming ~ 22% of 480 or 930 mg choline/d as methyl-d9-
choline from study wk-6 till delivery. Paired t tests were conducted in comparing the 
enrichment of corresponding choline metabolite among three compartments. Different letters 
(a, b, c) indicate differences between compartments at P-values < 0.001.  Similar results were 
obtained when the analyses were performed separately for each choline intake group. 
Abbreviations: DMG, dimethylglycine; PC, phosphatidylcholine; SM, sphingomyelin 
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DISCUSSION 
This study employed stable isotope methodology to investigate the effect of 
pregnancy and choline intake on the metabolic use of orally consumed choline in humans. 
Three main findings emerged: (i) pregnancy increases the production of PC through both the 
CDP-choline and PEMT pathways; (ii) PEMT-PC is selectively transported to the fetus; and 
(iii) a choline intake exceeding current recommendations partially restores the pregnancy-
induced alterations in choline metabolism.   
Effect of pregnancy on choline metabolism 
Pregnancy increases choline partitioning to the CDP-choline pathway at the expense of 
betaine synthesis 
Pregnant (versus nonpregnant) women used more choline for PC synthesis through 
the CDP-choline pathway (Figure 3) as indicated by a lower enrichment ratio of d9-
betaine:d9-PC. The enhanced use of choline for PC production via the CDP-choline pathway 
is due in part to the hepatic lipid load experienced by women during late pregnancy [23]. 
Specifically, PC is required for the biosynthesis of very low-density lipoproteins (VLDL), 
which mediate the export of lipid from liver into circulation. Pregnant (versus nonpregnant) 
women also exhibited a lower d9-betaine:d9-choline enrichment ratio as well as  diminished 
circulating concentrations of metabolites produced in the oxidative pathway including  
betaine, dimethylglycine, sarcosine, and methionine [4]. Thus, in the face of enhanced use of 
choline for PC production by the CDP-choline pathway, third trimester pregnant women 
require substantially more choline than their nonpregnant counterparts to maintain an 
adequate supply of choline derived methyl groups for one-carbon metabolism.  
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Figure 3 legend 
A working hypothesis of pregnancy induced alterations in choline metabolic pathways. 
Pregnancy reduces the use of orally consumed choline for betaine synthesis, but enhances the 
use of choline for PC synthesis through CDP-choline pathway, enhances the use of betaine 
for methionine synthesis and PC synthesis through PEMT pathway, and enhances the use of 
endogenously produced choline as a methyl donor.  
Boxed (solid and dashed) metabolites are those whose enrichment were quantified in the 
study; solid box, the metabolite enrichment higher or similar in pregnant compared to 
nonpregnant women; dashed box, the metabolite enrichment lower in pregnant compared to 
nonpregnant women. 
Thick arrow, metabolic flux enhanced in third trimester pregnant versus nonpregnant women; 
dashed arrow, metabolic flux attenuated in third trimester pregnant versus nonpregnant 
women. 
Abbreviations: DMG, dimethylglycine; SAR, sarcosine; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; 
SM, sphingomyelin; PEMT, phosphatidylethanolamine N-methyltransferase. 
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Pregnancy increases the use of choline derived methyl groups for PC synthesis through 
PEMT pathway  
Despite an enhanced partitioning of orally consumed choline to the CDP-choline 
pathway during late pregnancy, the use of choline derived methyl groups for PC synthesis 
through the PEMT pathway was elevated in pregnant versus nonpregnant women (Figure 3). 
Specifically, the incremental labeling of the plasma PC pool with PEMT-PC did not differ 
between pregnant and nonpregnant women.  As the PC pool size is approximately 50% 
greater among pregnant versus nonpregnant women, these data indicate that flux of choline 
derived methyl groups through the PEMT pathway is enhanced during late pregnancy.  The 
high demand for methyl groups by the PEMT pathway during pregnancy is consistent with its 
upregulation by estrogen [17, 18] which rises during the second half of gestation [19, 20].  
It is also noteworthy that the enrichment of d3-choline, the hydrolysis product of 
PEMT-PC, was higher in pregnant versus nonpregnant women. The higher enrichment of d3-
choline along with the higher enrichment ratio of d3-choline:d3-PC in pregnant versus 
nonpregnant women suggests that pregnant women catabolize more PEMT-PC in order to 
generate free choline. The enhanced hydrolysis of PEMT-PC may explain the rise in plasma 
free choline during the second half of gestation. Whether the hydrolysis of PC derived from 
the CDP-choline pathway contributes to the elevation of plasma free choline concentration 
during late pregnancy cannot be determined as the labeling strategy used in the present study 
does not distinguish between orally consumed d9-choline and d9-choline liberated from d9-
PC.  
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Pregnancy increases the use of choline derived methyl groups for methionine biosynthesis 
Although less betaine was synthesized from choline in pregnant versus nonpregnant 
women (i.e. lower d9-betaine:d9-choline enrichment ratio in pregnant women), more betaine 
was utilized for methionine synthesis in pregnant women (Figure 3).  Specifically, d3-
methionine enrichment was elevated among pregnant (versus nonpregnant) women as was 
the enrichment ratio of d3-methionine:(d3+d9)-betaine. Thus, the 50% lower plasma betaine 
concentration observed in late pregnancy likely arises from both reduced betaine synthesis 
and enhanced utilization of betaine for methionine production.   
PEMT-PC is selectively directed towards the fetus 
The stepwise increase in d3-PC enrichment, but not d9-PC enrichment, from the 
maternal to the fetal compartment implies that PEMT-PC is selectively directed towards the 
fetus.  This partitioning of PEMT-PC towards the fetus may be due to its enrichment with 
DHA.  Specifically, compared to the CDP-choline pathway, the PEMT pathway produces a 
PC molecule that is enriched in DHA [15, 24, 25], a long chain unsaturated fatty acid that is 
critical for fetal brain development [26, 27]. Once made, the PC-DHA molecule can be 
incorporated into VLDL and exported into circulation.  The circulating PC-DHA molecule is 
subsequently available to the peripheral tissues including the placenta and developing fetus.   
A choline intake exceeding current recommendations may be needed to support the demands 
of pregnancy  
The higher choline intake (930 versus 480 mg/d) among pregnant women restored the 
partitioning of choline between the CDP-choline and choline oxidative pathways to the 
nonpregnant state.  Specifically, a doubling of maternal choline intake during the later part of 
pregnancy yielded a d9-betaine:d9-PC enrichment ratio that did not differ (P = 0.9) from 
nonpregnant women consuming 480 mg choline/d. In addition, consumption of 930 mg 
choline/d among pregnant women elevated their plasma betaine concentrations to a level that 
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was closer to that of nonpregnant women consuming 480 mg choline/d [4]. These data 
suggest that a choline intake exceeding current recommendations may be needed to support 
both PC production via the CDP-choline pathway and choline mediated one-carbon 
metabolism. 
In addition, a higher choline intake enhanced the use of choline as a methyl donor for 
PC synthesis via the PEMT pathway among both pregnant and nonpregnant women.  
Specifically, consumption of 930 versus 480 mg choline/d yielded higher enrichment ratios 
of d9-betaine:d9-choline, (d3+d6)-PC: d9-choline, and (d3+d6)-PC:d9-PC independent of 
reproductive state. Moreover, a higher choline intake stimulated PC production through the 
PEMT pathway among nonpregnant women. Specifically, the incremental labeling of the 
plasma PC pool with PEMT-PC was greater among nonpregnant women consuming 930 
versus 480 mg choline/d. The up-regulated activity of the PEMT pathway among third 
trimester pregnant women (versus nonpregnant women) may have precluded the stimulatory 
effect of choline on PEMT activity during late pregnancy.  Collectively these data suggest 
that a higher choline intake may stimulate the PEMT pathway and thus mobilize PC-DHA to 
peripheral tissues among nonpregnant women and presumably among pregnant women at an 
earlier stage in gestation.  
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CONCLUSION AND IMPLICATIONS 
The enhanced use of choline for PC production via both the CDP-choline and PEMT 
pathways demonstrates the substantial demand for choline during late pregnancy. Our finding 
that a choline intake exceeding current recommendations restores the partitioning of choline 
between the CDP-choline pathway and betaine synthesis pathways among pregnant women 
(as compared to nonpregnant women consuming 480 mg choline/d) suggests that current 
recommendations may be suboptimal during gestation.  The selective partitioning of PEMT-
PC to the fetal compartment may imply a unique requirement of PEMT-PC for the 
developing fetus. 
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AFTERWORD 
MTHFR 677TT genotype increases the use of choline as a methyl donor 
Genetic variation can modify disease risk and more than 800 human studies 
examining the relationship between MTHFR C677T genotype and disease risk have been 
published since its discovery in 1995 [1]. The 677TT genotype has been shown to increase 
the risk of cardiovascular disease, neural tube defects, cognitive impairments and certain 
types of cancer [2, 3]. Nevertheless, it is well established that a high folate intake can abolish 
the adverse effects of the MTHFR 677TT genotype [4] thereby illustrating the importance of 
personalized nutrition, which bases nutrient recommendations on an individual’s genetic 
profile. The findings of my dissertation work demonstrate that choline may also be useful in 
mitigating the adverse effects of the MTHFR 677TT genotype.  Specifically, in the face of 
impaired ability to produce 5-methyl-THF (the product of MTHFR), individuals with the 
MTHFR 677TT genotype used more choline as a methyl donor.  Moreover, a choline intake 
level exceeding current recommendations increased the use of choline derived methyl groups 
only in the 677TT but not 677CC genotype.  This unique ability to respond to extra choline 
among those with the MTHFR 677TT genotype coupled with their greater reliance on choline 
as a methyl donor implies that a choline intake exceeding current recommendations may 
improve health outcomes among this genetic sub-group. 
 
A maternal choline intake exceeding current recommendations increases the use of choline 
as a methyl donor in the maternal and fetal compartments 
Pregnancy is associated with a higher demand for choline due to accelerated 1-C 
metabolism and the formation of new membranes as cells undergo division [5]. Pregnancy 
causes a pronounced reduction of choline pools in rodents consuming a normal chow diet [6], 
indicating that the need for this nutrient by the mother and the fetus may exceed the amount 
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consumed by the mother and the amount produced by the endogenous pathway (i.e., 
phosphatidylethanolamine N-methyltransferase pathway). Moreover, supplementing the 
maternal rat diet with additional choline (approximately 4 times the amount in normal chow) 
leads to a significant enhancement of memory function of the adult offspring and 
substantially lessens aging-related memory decline [7-10]. The lasting beneficial effects of 
maternal supplemental choline on cognitive functioning in the adult offspring are mediated in 
part by alterations in genomic DNA/histone methylation [11, 12].   
The findings of my dissertation document depletion of choline derived methyl donors 
among third trimester pregnancy women as well as enhanced biosynthesis of PC through 
both the CDP-choline and denovo pathways. Notably, consumption of a higher choline intake 
partially restores these pregnancy induced metabolic alterations and leads to greater use of 
choline as a methyl donor in both the maternal and fetal compartment. The implications of 
the effects of a higher maternal choline intake during late pregnancy have been elucidated in 
separate research publications by our research group [13-14]. For example, a higher maternal 
choline intake alters the methylation of cortisol regulating genes resulting in lower circulating 
concentrations of the stress hormone, cortisol [13]. Collectively, the study findings suggest 
that consuming extra choline during pregnancy increases the availability of choline derived 
methyl groups with downstream effects on “programming” baby’s responsiveness to stress.     
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